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A B S T R A C T
Background
Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked
seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become
seizure-free, and to go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.
Worldwide, sodium valproate and phenytoin are commonly used antiepileptic drugs for monotherapy treatment. It is generally believed
that phenytoin is more effective for focal onset seizures, and that sodium pvalproate is more effective for generalised onset tonic-clonic
seizures (with or without other generalised seizure types). This review is one in a series of Cochrane Reviews investigating pair-wise
monotherapy comparisons. This is the latest updated version of the review first published in 2001, and updated in 2013 and 2016.
Objectives
To review the time to treatment failure, remission andfirst seizure of sodiumvalproate compared to phenytoinwhenused asmonotherapy
in people with focal onset seizures or generalised tonic-clonic seizures (with or without other generalised seizure types).
Search methods
We searched the Cochrane Epilepsy Group’s Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform ICTRP on
19 February 2018. We handsearched relevant journals, contacted pharmaceutical companies, original trial investigators and experts in
the field.
Selection criteria
Randomised controlled trials (RCTs) comparing monotherapy with either sodium valproate or phenytoin in children or adults with
focal onset seizures or generalised onset tonic-clonic seizures
Data collection and analysis
This was an individual participant data (IPD) review. Our primary outcome was time to treatment failure and our secondary outcomes
were time to first seizure post-randomisation, time to six-month, and 12-month remission, and incidence of adverse events. We used
Cox proportional hazards regression models to obtain trial-specific estimates of hazard ratios (HRs) with 95% confidence intervals
(CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI.
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Main results
We included 11 trials in this review and IPDwere available for 669 individuals out of 1119 eligible individuals from five out of 11 trials,
60% of the potential data. Results apply to focal onset seizures (simple, complex and secondary generalised tonic-clonic seizures), and
generalised tonic-clonic seizures, but not other generalised seizure types (absence or myoclonus seizure types). For remission outcomes,
a HR of less than 1 indicates an advantage for phenytoin, and for first seizure and treatment failure outcomes a HR of less than 1
indicates an advantage for sodium valproate.
The main overall results were: time to treatment failure for any reason related to treatment (pooled HR adjusted for seizure type 0.88,
95% CI 0.61 to 1.27; 5 studies; 528 participants; moderate-quality evidence), time to treatment failure due to adverse events (pooled
HR adjusted for seizure type 0.77, 95% CI 0.44 to 1.37; 4 studies; 418 participants; moderate-quality evidence), time to treatment
failure due to lack of efficacy (pooled HR for all participants 1.16 (95% CI 0.71 to 1.89; 5 studies; 451 participants; moderate-quality
evidence). These results suggest that treatment failure for any reason related to treatment and treatment failure due to adverse events
may occur earlier on phenytoin compared to sodium valproate, while treatment failure due to lack of efficacy may occur earlier on
sodium valproate than phenytoin; however none of these results were statistically significant.
Results for time to first seizure (pooled HR adjusted for seizure type 1.08, 95% CI 0.88 to 1.33; 5 studies; 639 participants; low-quality
evidence) suggest that first seizure recurrence may occur slightly earlier on sodium valproate compared to phenytoin. There were no
clear differences between drugs in terms of time to 12-month remission (pooled HR adjusted for seizure type 1.02, 95% CI 0.81 to
1.28; 4 studies; 514 participants; moderate-quality evidence) and time to six-month remission (pooled HR adjusted for seizure type
1.05, 95% CI 0.86 to 1.27; 5 studies; 639 participants; moderate-quality evidence).
Limited information was available regarding adverse events in the trials and we could not make comparisons between the rates of adverse
events on sodium valproate and phenytoin. Some adverse events reported with both drugs were drowsiness, rash, dizziness, nausea and
gastrointestinal problems. Weight gain was also reported with sodium valproate and gingival hypertrophy/hyperplasia was reported on
phenytoin.
The methodological quality of the included trials was generally good, however four out of the five trials providing IPD for analysis
were of an open-label design, therefore all results were at risk of detection bias. There was also evidence that misclassification of seizure
type may have confounded the results of this review, particularly for the outcome ’time to first seizure’ and heterogeneity was present
in analysis of treatment failure outcomes which could not be explained by subgroup analysis by epilepsy type or by sensitivity analysis
for misclassification of seizure type. Therefore, for treatment failure outcomes we judged the quality of the evidence to be moderate to
low, for ’time to first seizure’ we judged the quality of the evidence to be low, and for remission outcomes we judged the quality of the
evidence to be moderate.
Authors’ conclusions
We have not found evidence that a significant difference exists between valproate and phenytoin for any of the outcomes examined in
this review. However detection bias, classification bias and heterogeneity may have impacted on the results of this review. We did not
find any outright evidence to support or refute current treatment policies. We recommend that future trials be designed to the highest
quality possible with consideration of masking, choice of population, classification of seizure type, duration of follow-up, choice of
outcomes and analysis, and presentation of results.
P L A I N L A N G U A G E S U M M A R Y
Sodium valproate versus phenytoin monotherapy (single drug treatment) for epilepsy
This is an updated version of the Cochrane Review previously published in Issue 4, 2016 of the Cochrane Database of Systematic Reviews.
Background
Epilepsy is a common neurological disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied
two types of epileptic seizures in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and
move throughout the brain; and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole
hemisphere of the brain or part of a lobe of the brain). Focal seizures may become generalised (secondary generalisation) and move
from one part of the brain throughout the brain. For around 70% of people with epilepsy, a single antiepileptic medication can control
generalised onset or focal onset seizures.
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Objective
Sodium valproate and phenytoin are commonly used treatments for individuals with epilepsy. The aim of this review was to compare
how effective these drugs are at controlling seizures and whether individuals choose to stop taking these treatments (treatment failure),
to inform a choice between these drugs.
Methods
The last search for trials for this review was 19 February 2018. We assessed the evidence from 11 randomised controlled clinical trials
comparing sodium valproate to phenytoin and we were able to combine data for 699 people from five of the 11 trials; for the remaining
450 people from six trials, data were not available to use in this review.
Key results
This review of trials found no difference between these two drugs for the seizure types studied for the outcomes of treatment failure
(withdrawal from treatment) and controlling seizures (recurrence of seizures or achievement of a seizure-free period (remission) of 6
months or 12 months). The review also found no evidence to support or refute the policy of using sodium valproate for generalised
onset tonic-clonic seizures and phenytoin for focal onset seizures.
However, up to 49% of people within the trials classified as having generalised seizures may have had their seizure type wrongly
diagnosed and these people may have been experiencing focal seizures or an uncertain seizure type, and this misclassification may have
influenced the results of this review. We were unable to address the issue of preferring sodium valproate for generalised onset seizure
types other than tonic-clonic, such as absence or myoclonic seizures.
Quality of the evidence
We judged the quality of the evidence as moderate to low for the evidence of treatment failure, moderate for remission outcomes and
low for seizure outcomes as it is likely that misclassification of seizure type influenced the results of the review. Within four of the five
trials providing data for this review, the design of the trial meant that the people and treating clinicians knew which medication they
were taking. This design may have influenced the results.
Conclusions
Sodium valproate and phenytoin are commonly used treatments for individuals with epilepsy, but we found no difference between these
treatments for the outcomes of this review or between seizure types. More information is needed and we recommend that all future
trials comparing these medications, or any other antiepileptic medications, should be designed using high-quality methods. Seizure
types of people included in trials should also be classified very carefully to ensure that the results are also of high quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Sodium valproate compared with phenytoin monotherapy for epilepsy
Patient or population: adults and children with newly-onset focal onset or generalised tonic-clonic seizures
Settings: outpat ients
Intervention: sodium valproate
Comparison: phenytoin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenytoin Sodium valproate
Time to treatment fail-
ure (any reason related
to treatment)
All participants
Range of follow-up: 0 to
4256 days
The median t ime to
treatment failure was
2361 days in the pheny-
toin group
The median t ime to
treatment failure was
2545 days (184 days
longer) in the sodium
valproate group
HR 0.88
(0.61 to 1.27)a
528
(5 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for val-
proate
There was also no sta-
t ist ically signif icant dif -
ference between drugs
in treatment failure due
to adverse events: HR0.
77 (95%CI 0.44 to 1.37,
P = 0.38) or treatment
failure due to lack of ef -
f icacy: HR 1.16 (95% CI
0.71 to 1.89, P = 0.55)
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: focal onset
seizures
Range of follow-up: 0 to
4256 days
The median t ime to
treatment failure was
1838 days in the pheny-
toin group
The median t ime to
treatment failure was
1772 days (66 days
shorter) in the sodium
valproate group
HR 0.83
(0.50 to 1.38)
187
(4 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for val-
proate
There was also no sta-
t ist ically signif icant dif -
ference between drugs
in treatment failure due
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to adverse events: HR0.
81 (95%CI 0.34 to 1.90,
P = 0.62) or treatment
failure due to lack of ef -
f icacy: HR 1.01 (95% CI
0.55 to 1.85, P = 0.98)
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: generalised on-
set seizures (tonic-clonic
only)
Range of follow-up: 0 to
4394 days
The 25th percent ile* *
of t ime to treatment
failure was 1488 days
in the phenytoin group
The 25th percent ile* *
of t ime to treatment
failure was 1778 days
(290 days longer) in the
sodium valproate group
HR 0.94
(0.55 to 1.61)
341
(5 studies)
⊕⊕⊕©
Lowb,c
HR < 1 indicates a clin-
ical advantage for val-
proate
There was also no sta-
t ist ically signif icant dif -
ference between drugs
in treatment failure due
to adverse events: HR0.
75 (95%CI 0.35 to 1.60,
P = 0.46) or treatment
failure due to lack of ef -
f icacy: HR 1.51 (95% CI
0.66 to 3.45, P = 0.33)
* Illustrat ive risks in the sodium valproate and phenytoin groups are calculated at the median t ime to treatment failure (i.e. the t ime to 50%of part icipants failing or withdrawing
f rom allocated treatment) within each group across all t rials. The relat ive ef fect (pooled HR) shows the comparison of ’t ime to treatment failure’ between the treatment groups
* * The 25th percent ile of t ime to treatment failure (i.e. the t ime to 25% of part icipants failing or withdrawing f rom allocated treatment) is presented for the subgroup with
generalised seizures as less than 50% of part icipants failed/ withdrew f rom treatment, therefore the median t ime could not be calculated
Abbreviations: CI: conf idence interval; HR: hazard rat io.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aPooled HR for all part icipants adjusted for seizure type.
bDowngraded once as risk of bias judged high for three unblinded studies (De Silva 1996; Heller 1995; Ramsay 1992); lack of
blinding may have impacted on the withdrawal rates and treatment failure rates in the trials.
cDowngraded once due to inconsistency: a large amount of heterogeneity is present within analysis (I² = 59%) which could
not be explained by sensit ivity analysis for potent ial m isclassif icat ion of epilepsy type.5
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B A C K G R O U N D
This is an updated version of the original Cochrane review pub-
lished in 2001 (Tudur Smith 2001), updated in 2013 and 2016
(Nolan 2013a; Nolan 2016a).
Description of the condition
Epilepsy is a common neurological condition in which abnormal
electrical discharges from the brain cause recurrent unprovoked
seizures. Epilepsy is a disorder of many heterogenous seizure types,
with an estimated incidence of 33 to 57 per 100,000 person-
years worldwide (Annegers 1999; Hirtz 2007; MacDonald 2000;
Olafsson 2005; Sander 1996), accounting for approximately 1%
of the global burden of disease (Murray 1994). The lifetime risk of
epilepsy onset is estimated to be 1300 to 4000 per 100,000 person-
years (Hauser 1993; Juul Jenson 1983), and the lifetime preva-
lence could be as large as 70 million people worldwide (Ngugi
2010). It is believed that with effective drug treatment, up to 70%
of individuals with active epilepsy have the potential to go into
long-term remission shortly after starting drug therapy (Cockerell
1995; Hauser 1993; Sander 2004), and around 70% of individ-
uals can achieve seizure freedom using a single antiepileptic drug
in monotherapy (Cockerell 1995). Current National Institute for
Health and Care Excellence (NICE) guidelines recommend that
both adults and children with epilepsy should be treated with
monotherapy wherever possible (NICE 2012). The remaining
30%of individuals experience refractory or drug-resistant seizures,
which often require treatment with combinations of antiepileptic
drugs or alternative treatments, such as epilepsy surgery (Kwan
2000).
We studied two seizure types in this review: generalised onset
seizures inwhich electrical discharges begin in one part of the brain
and move throughout the brain, and focal onset seizures in which
the seizure is generated in and affects one part of the brain (the
whole hemisphere of the brain or part of a lobe of the brain).
Description of the intervention
Themajority of people with epilepsy have their seizures controlled
by a single drug (monotherapy) (Cockerell 1995). Worldwide,
sodium valproate and phenytoin are commonly used antiepileptic
drugs licensed for monotherapy. Phenytoin is used as a first-line
drug in low- and middle-income countries as it is a low-cost drug
and can be given as a single daily dose, but is no longer consid-
ered a first-line agent in the USA and much of Europe due to
worries over adverse events (Wallace 1997; Wilder 1995). Pheny-
toin is associated with long-term cosmetic changes including gum
hyperplasia, acne and coarsening of the facial features (Mattson
1985; Scheinfeld 2003), as well as low folic acid levels, predispos-
ing participants to megaloblastic anaemia (Carl 1992), and is as-
sociated with congenital abnormalities (Gladstone 1992; Morrow
2006; Meador 2008; Nulman 1997), particularly foetal hydan-
toin syndrome (Scheinfeld 2003). Furthermore, due to the phar-
macokinetic profile of phenytoin, the plasma concentrations are
difficult to predict and dosing will usually need to be informed
by measuring plasma concentration. Sodium valproate has also
been shown to have teratogenic properties (Canger 1999;Morrow
2006; Tomson 2011), and is particularly associated with spina
bifida and cardiac, craniofacial, skeletal and limb defects known
as ’valproate syndrome’ (Ornoy 2009). Systematic reviews have
found sodium valproate to have the highest incidence of congen-
ital malformations of standard antiepileptic drugs (Meador 2008;
Weston 2017), and recent studies have shown an increased preva-
lence of neurodevelopmental disorders following prenatal sodium
valproate exposure (Bromley 2013; Bromley 2014). Sodium val-
proate is also associated with weight gain in adults and children
(Dinesen 1984; Easter 1997; Egger 1981; Novak 1999).
How the intervention might work
It is generally believed that sodium valproate monotherapy is more
effective thanphenytoinmonotherapy in generalised onset seizures
(generalised tonic-clonic seizures, absence, and myoclonus), while
phenytoin monotherapy is more effective than sodium valproate
monotherapy in focal onset seizures (simple focal, complex fo-
cal, and secondary generalised tonic-clonic seizures) (Chadwick
1994), although there is no conclusive evidence from individual
randomised controlled trials (RCTs) to support this belief. Ev-
idence in favour of sodium valproate for generalised seizures is
predominantly anecdotal from observational studies, suggesting
a dramatic benefit with sodium valproate in juvenile myoclonic
epilepsy (Delgado-Escueta 1984; Penry 1989), and reports of effi-
cacy of sodium valproate against absence seizures (Bourgeois 1987;
Jeavons 1977). The results of two RCTs, recruiting children in-
dicate that sodium valproate may be better tolerated in children
than phenytoin (De Silva 1996; Thilothammal 1996); twice as
many children experienced at least one side effect on phenytoin
than sodium valproate in Thilothammal 1996, and phenytoin was
more likely to be withdrawn due to unacceptable side effects than
sodium valproate in De Silva 1996.
Some animal models have suggested that phenytoin has either no
effect in absence seizures or may in fact worsen seizures (Liporace
1994). There is also anecdotal evidence that phenytoin may cause
paradoxical intoxication (increased seizure frequency with in-
creased anticonvulsant dose) and encephalopathy (Troupin 1975;
Vallarta 1974).
Why it is important to do this review
Accepting that phenytoin should not be a drug of first choice for
individuals experiencing absence, myoclonic and atonic seizures,
we still have insufficient evidence fromRCTs to guide a choice be-
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tween sodium valproate and phenytoin for individuals with gen-
eralised onset tonic-clonic seizures or focal onset seizures. The aim
of this review, therefore, is to summarise efficacy and tolerability
data from existing trials comparing valproate and phenytoin when
used as monotherapy treatments.
There are difficulties in undertaking a systematic review of epilepsy
monotherapy trials, as the important efficacy outcomes require
analysis of time-to-event data (for example, time to first seizure
after randomisation). Although methods have been developed
to synthesise time-to-event data using summary information
(Parmar 1998;Williamson 2002), the appropriate statistics are not
commonly reported in published epilepsy trials (Nolan 2013d;
Williamson 2000).
Furthermore, although seizure data have been collected in most
epilepsy monotherapy trials, there has been no uniformity in the
definition and reporting of outcomes. For example, trials may re-
port time to 12-month remission but not time to first seizure or
vice versa, or some trials may define time to first seizure from the
date of randomisation, while others use date of achieving main-
tenance dose. Trial investigators have also adopted differing ap-
proaches to the analysis, particularly with respect to the censoring
of time-to-event data. For these reasons, we performed this review
using individual participant data (IPD) which helps to overcome
these problems. This review is one in a series of Cochrane IPD re-
views investigating pair-wise monotherapy comparisons (Marson
2000; Nevitt 2017b; Nolan 2013b; Nolan 2013c; Nolan 2016b;
Nolan 2016c; Nevitt 2018). These data have also been included
in IPD network meta-analyses of antiepileptic drug monotherapy
(Nevitt 2017a; Tudur Smith 2007).
O B J E C T I V E S
To review the time to treatment failure, remission and first
seizure of sodium valproate compared to phenytoin when used
as monotherapy in people with focal onset seizures or generalised
tonic-clonic seizures (with or without other generalised seizure
types).
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs) using either:
◦ an adequate method of allocation concealment (e.g.
sealed opaque envelopes); or
◦ a ’quasi’ method of randomisation (e.g. allocation by
date of birth).
• Studies may be double-blind, single-blind or unblinded.
• Studies must include a comparison of sodium valproate
monotherapy with phenytoin monotherapy in individuals with
epilepsy.
Types of participants
• We included children or adults with focal onset seizures
(simple focal, complex focal or secondarily generalised tonic-
clonic seizures) or generalised onset tonic-clonic seizures, with or
without other generalised seizure types (in other words, those
who had only generalised tonic-clonic seizures and those who
had both generalised onset tonic-clonic seizures and generalised
seizures of other types (e.g. absence, myoclonic etc.)).
• We excluded individuals with other generalised seizure
types alone without generalised tonic-clonic seizures (e.g. those
who had only absence seizures without any generalised clonic
tonic-seizures) due to differences in first-line treatment
guidelines for other generalised seizure types (NICE 2012).
• We included individuals with a new diagnosis of epilepsy,
or who have had a relapse following withdrawal of antiepileptic
monotherapy.
Types of interventions
Sodium valproate or phenytoin as monotherapy. For brevity,
sodium valproate is referred to a ’valproate’ herein.
Types of outcome measures
Below is a list of outcomes investigated in this review. Reporting
of these outcomes in the original trial report was not an eligibility
requirement for inclusion in this review.
Primary outcomes
• Time to treatment failure (retention time).
This is a combined outcome reflecting both efficacy and tolerabil-
ity, as the following may have lead to failure of treatment: contin-
ued seizures, side effects, noncompliance or the initiation of addi-
tional add-on treatment. This is an outcome to which the partic-
ipant makes a contribution and is the primary outcome measure
recommended by the Commission on Antiepileptic Drugs of the
International League Against Epilepsy (ILAE 1998; ILAE 2006).
Time to treatment failure is considered according to three defini-
tions.
• Time to treatment failure, for any treatment-related reason
(continued seizures, side effects, noncompliance or the initiation
of additional add-on treatment).
• Time to treatment failure, due to adverse events (i.e. side
effects).
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• Time to treatment failure, due to lack of efficacy (i.e.
continued seizures).
Secondary outcomes
• Time to first seizure (post-randomisation).
• Time to achieve 12-month remission (seizure-free period).
• Time to achieve six-month remission (seizure-free period).
• Incidence of adverse events.
Search methods for identification of studies
Electronic searches
We searched the following databases. We did not impose any lan-
guage restrictions.
• The Cochrane Epilepsy Group’s Specialised Register (19
February 2018) using the search strategy outlined in Appendix 1.
• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 2) in the Cochrane Library (searched
19 February 2018) using the search strategy outlined in
Appendix 2.
• MEDLINE (Ovid, 1946 to 19 February 2018) using the
search strategy outlined in Appendix 3.
• SCOPUS (last search 19 February 2013) using the search
strategy outlined in Appendix 4. We searched SCOPUS as an
alternative to Embase, but this is no longer necessary, because
randomised and quasi-RCTs in Embase are now included in
CENTRAL, so we will not be updating the SCOPUS search.
• ClinicalTrials.gov (19 February 2018) using the search
terms ’phenytoin AND valproate | Epilepsy’.
• WHO International Clinical Trials Registry Platform
ICTRP (19 February 2018) using the search terms ’valproate and
phenytoin and epilepsy’.
Searching other resources
In addition, we handsearched relevant journals, reviewed the ref-
erence lists of retrieved studies to search for additional reports of
relevant studies, contacted Sanofi (manufacturers of valproate in
Europe), Abbott (manufacturers of valproate in the USA), Parke-
Davis (manufacturers of phenytoin), and experts in the field for
information about any ongoing studies.
Data collection and analysis
Selection of studies
Two review authors (SJN and AGM) independently assessed trials
for inclusion, resolving any disagreements by mutual discussion.
Data extraction and management
We requested the following individual participant data (IPD) for
all trials meeting our inclusion criteria.
• Trial methods
◦ method of generation of random list
◦ method of concealment of randomisation
◦ stratification factors
◦ blinding methods
• Participant covariates
◦ gender
◦ age
◦ seizure types
◦ time between first seizure and randomisation
◦ number of seizures prior to randomisation (with dates)
◦ presence of neurological signs
◦ electroencephalographic (EEG) results
◦ computerised tomography/magnetic resonance
imaging (CT/MRI) results
• Follow-up data
◦ treatment allocation
◦ date of randomisation
◦ dates of follow-up
◦ dates of seizures post-randomisation or seizure
frequency data between follow-up visits
◦ dates of treatment withdrawal or treatment failure and
reasons for treatment withdrawal or treatment failure
◦ dose
◦ dates of dose changes
For each trial for which IPD were not obtained, we carried out
an assessment to see whether any relevant aggregate level data had
been reported. If possible, SJN extracted any aggregate level data
from publications and extracted data were verified by JW.
For three trials, seizure data were provided in terms of the number
of seizures recorded between clinic visits rather than specific dates
of seizures (Craig 1994; Ramsay 1992; Turnbull 1985). To enable
time-to-event outcomes to be calculated, we applied linear inter-
polation to approximate the dates on which seizures occurred. For
example, if four seizures were recorded between two visits which
occurred on 1 March and 1 May (an interval of 61 days), then
date of first seizure would be approximately 13 March. This al-
lowed an estimate of the time to achieve six-month and 12-month
remission and the time to first seizure to be computed.
We calculated time to achieve six-month and 12-month remission
from the date of randomisation to the date (or estimated date)
the individual had first been free of seizures for six or 12 months,
respectively. If the personhadone ormore seizure(s) in the titration
period, a six-month or 12-month seizure-free period could also
occur between the estimated date of the last seizure in the titration
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period and the estimated date of the first seizure in themaintenance
period.
We calculated time to first seizure from the date of randomisation
to the date that their first seizure was estimated to have occurred.
If seizure data were missing for a particular visit, these outcomes
were censored at the previous visit. These outcomes were also
censored if the individual died or if follow-up ceased prior to the
occurrence of the event of interest. These methods had been used
in the remaining two trials for which outcome data were provided
directly (De Silva 1996; Heller 1995).
Treatment failure datawere not available for one trial (Craig 1994).
For two trials, we extracted dates and reason for treatment failure
from trial case report forms for the original review (De Silva 1996;
Heller 1995). Two review authors (SJN and AGM) independently
extracted data from all case report forms, resolving disagreements
by discussion and reconsidering the case report forms. For the
remaining trials (Ramsay 1992; Turnbull 1985), data on length of
time spent in trial and reason for withdrawal from treatment or
treatment failure were provided directly.
Time to treatment failure was calculated as date of randomisation
to date of treatment failure. For the analysis of time-to-event, we
defined an ’event’ as treatment failure because of reasons related to
the treatment (i.e. lack of efficacy, adverse events, or both lack of
efficacy and adverse events), non-compliance with the treatment
regimen, withdrawal of consent from the trial, etc.). We censored
the outcome if treatment failure or withdrawal of treatment was
for reasons not related to the trial treatment: i.e. loss to follow-up,
death (not treatment or epilepsy-related), withdrawal of treatment
due to remission, etc. We also censored individuals who were still
on allocated treatment at the date of the end of follow-up. We
considered documented reasons for treatment failure or treatment
withdrawal on a case-by-case basis in relation to treatment; two
authors (SJN andAGM) independently classified reasons for treat-
ment failure as ’events’ or ’censored’ and resolved any disagree-
ments by discussion.
For the analysis of ’time to treatment failure due to adverse events,’
only treatment failures which were documented to be due to ad-
verse events (either as a sole reason or due to both a lack of efficacy
and adverse events) were classed as an ’event’ within time-to-event
analyses and all other reasons for treatment failure were censored.
Similarly, for the analysis of ’time to treatment failure due to lack of
efficacy’ only treatment failures which were documented to be due
to lack of efficacy (i.e. continued seizures, either as a sole reason or
due to both a lack of efficacy and adverse events) were classed as
an ’event’ within time-to-event analyses and all other reasons for
treatment failure were censored.
Two trials presented times at which the allocated drug was with-
drawn and the reason for treatment failure in the trial publica-
tion for each individual (Forsythe 1991; Shakir 1981). Hence,
these two trials could be incorporated into the analysis of ’time to
treatment failure’; one of the trials also presented information by
seizure type (focal onset or generalised onset seizures) and there-
fore could also be included in the stratified analysis for ’time to
treatment failure’ (Shakir 1981).
Shakir 1981 presents ’time on trial drug’ in months for each par-
ticipant; therefore to calculate ’time to treatment failure’, we as-
sumed that if ’time spent on trial drug’ was five months, the in-
dividual spent five full months (152 full days) on the trial drug
before treatment failure. Forsythe 1991 presents ’withdrawal and
time of occurrence by month’ for each participant; therefore to
calculate ’time to treatment failure’, we assumed that if treatment
failure occurred during the fifth month, that the treatment failure
occurred halfway between the fifth and sixth month (i.e. partici-
pants spent 167 full days on treatment before treatment failure).
Assessment of risk of bias in included studies
Two review authors (SJN and JW) independently assessed the
risk of bias for each trial using the Cochrane ’Risk of bias’ tool,
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We rated each of the following six
domains as low, unclear or high risk of bias: method of generat-
ing random sequence, allocation concealment, blinding methods,
incomplete outcome data, selective outcome reporting and other
sources of bias. Any discrepancies in risk of bias judgements of the
two review authors were resolved by discussion. In the event of the
presence of high risk of bias in included trials (due to inadequate
allocation concealment or lack of blinding), we planned sensitivity
analyses excluding these trials.
Measures of treatment effect
We measured all outcomes in this review as time-to-event out-
comes with the hazard ratio (HR) and 95% confidence interval
(CI) used as the measure of treatment effect. We calculated out-
comes from IPD provided, where possible, or extracted from pub-
lished trials if possible.
Unit of analysis issues
We did not have any unit of analysis issues. The unit of allocation
and analysis was the individual for all included trials; and no trials
included in meta-analyses were of a repeated measures (longitudi-
nal) nature or of a cross-over design.
Dealing with missing data
For each trial that supplied IPD, we reproduced results from trial
results where possible and performed the following consistency
checks.
• We cross-checked trial details against any published report
of the trial and contacted original trial authors if we found
missing data, errors or inconsistencies. If trial authors could not
resolve inconsistencies between the IPD and the published data,
depending on the extent of the inconsistencies, we planned to
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perform sensitivity analysis or excluded the data from the meta-
analysis.
• We reviewed the chronological randomisation sequence and
checked the balance of prognostic factors, taking account of
factors stratified for in the randomisation procedure.
Assessment of heterogeneity
We assessed heterogeneity statistically using the Q test (P < 0.10
for significance) and the I² statistic (greater than 50% indicat-
ing considerable heterogeneity; Higgins 2003), and visually by in-
specting forest plots.
Assessment of reporting biases
Two review authors (SJN and JW) undertook all full quality and
risk of bias assessments. In theory, a review using IPD should over-
come issues of reporting biases, as unpublished data can be pro-
vided and unpublished outcomes calculated. Any selective report-
ing bias detected could be assessed with the ORBIT classification
system (Kirkham 2010).
Data synthesis
We carried out our analysis on an intention-to-treat basis (that
is, we analysed participants in the group to which they were ran-
domised, irrespective of which treatment they actually received).
Therefore, for the time-to-event outcomes, ’time to six-month re-
mission’, ’time to 12-month remission’, ’time to 24 month remis-
sion’ and ’time to first seizure post-randomisation’, we did not cen-
sor participants if treatment was withdrawn or if treatment failure
occurred but follow-up within the trial continued (e.g. if a partic-
ipant continued to be followed up on a different treatment).
For all outcomes, we investigated the relationship between the
time-to-event and treatment effect of the antiepileptic drugs. We
used Cox proportional hazards regression models to obtain trial-
specific estimates of log (HR) or treatment effect and associated
standard errors in Stata Statistical Software, version 14 (Stata
2015). Themodel assumes that the ratio of hazards (risks) between
the two treatment groups is constant over time (i.e. hazards are
proportional). We tested this proportional hazards assumption of
the Cox regression model for each outcome of each trial by testing
the statistical significance of a time varying covariate in the model.
We evaluated overall pooled estimates of HRs (with 95% CIs)
using the generic inverse variance method. We expressed results as
a HR and a 95% CI.
By convention, a HR greater than 1 indicates that an event is more
likely to occur earlier on valproate than on phenytoin. Hence,
for time to treatment failure or time to first seizure, a HR less
than 1 indicates a clinical advantage for valproate (e.g. HR = 0.8
would suggest a 20% reduction in hazard of treatment failure
from valproate compared to phenytoin), and for time to achieve
six-month and 12-month remission, a HR less than 1 indicates a
clinical advantage for phenytoin.
Subgroup analysis and investigation of heterogeneity
Due to the strong clinical belief that valproate is more effective
in generalised onset seizures, while phenytoin is more effective in
focal onset seizures, we have stratified all analyses by seizure type
(focal onset versus generalised onset), according to the classifica-
tion of main seizure type at baseline. We classified focal seizures
(simple or complex) and focal secondarily generalised seizures as
’focal epilepsy’.We classified primarily generalised seizures as ’gen-
eralised epilepsy’.We conducted a Chi² test of interaction between
treatment and epilepsy type.
If we found significant statistical heterogeneity to be present, we
performed meta-analysis with a random-effects model in addition
to a fixed-effect model, presenting the result of both models and
performing sensitivity analyses to investigate differences in study
characteristics.
Sensitivity analysis
One trial recruited only individuals with generalised onset tonic-
clonic seizures, some of whomwere experiencing other generalised
seizure types, such as absence or myoclonus (Ramsay 1992), and
all generalised seizure types were recorded during follow-up for
this trial. The remaining four trials recruited individuals with focal
onset seizures (simple/complex focal or secondarily generalised
tonic-clonic) and individuals with generalised onset tonic-clonic
seizures. For the individuals with generalised onset tonic-clonic
seizures recruited into these four trials, other generalised seizure
types were not recorded during follow-up. As a result, themajority
of the data from the five trials does not address the treatment of
generalised seizure types, such as absence ormyoclonus, but applies
only to generalised onset tonic-clonic seizures. In our primary
analysis, we use only the data for generalised onset tonic-clonic
seizures during follow-up as this is the most consistent approach;
we also report a sensitivity analysis which includes data on all
generalised seizure types fromRamsay 1992 for the outcomes ’time
to first seizure’ and ’time to six-month remission’ (Ramsay 1992
was less than one year duration so does not contribute to ’time to-
12 month remission’).
Misclassificationof seizure type is a recognised problem in epilepsy,
whereby some people with generalised seizures have been mistak-
enly classed as having focal onset seizures and vice versa. There is
clinical evidence that individuals with generalised onset seizures
are unlikely to have an ’age of onset’ greater than 25 to 30
years (Malafosse 1994). Such misclassification impacted upon
the results of three reviews in our series of pair-wise reviews for
monotherapy in epilepsy comparing carbamazepine to phenobar-
bitone, phenytoin and sodium valproate in which around 30% to
50% of participants analysed may have had their seizure type mis-
classified as generalised onset (Marson 2000; Nolan 2016c; Nevitt
2017b). Given the potential biases introduced into those reviews,
we examined the distribution of age at onset for individuals with
generalised seizures in the trials included in this review, to assess
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the potential impact of misclassification of seizure type on the out-
comes:
• 84 out of 86 individuals classified as having generalised
onset seizures (98%) in Craig 1994;
• 37 out of 71 individuals (52%) in Heller 1995;
• 30 out of 136 (22%) in Ramsay 1992;
• 2 out of 14 (14%) in Shakir 1981; and
• 35 out of 77 (45%) in Turnbull 1985.
Therefore, a total of up to 188 out of 384 individuals (49%) classi-
fied as having generalised onset seizures may have had their seizure
type misclassified (De Silva 1996 was a paediatric trial so no in-
dividuals over the age of 30 were recruited). Such a misclassifica-
tion could bias our results against finding an interaction between
treatment and seizure types (focal onset versus generalised onset).
We undertook the following two analyses to investigate misclassi-
fication.
• We reclassified all individuals with generalised seizures and
age at onset greater than 30 into an ’uncertain seizure type’
group.
• We reclassified individuals with generalised seizures and age
at onset greater than 30 as having focal onset seizures.
Summary of findings and quality of the evidence
(GRADE)
For the 2013 update, in a post hoc change from protocol, we have
added two ’Summary of findings’ tables to the review (outcomes
in the tables decided before the update started based on clinical
relevance).
Summary of findings for themain comparison reports the primary
outcome of ’time to treatment failure’ in the subgroups of par-
ticipants with focal onset seizures, generalised onset seizures and
overall adjusted by epilepsy type.
Summary of findings 2 reports the secondary outcomes of ’time
to first seizure’ and ’time to 12-month remission’ in the subgroups
of participants with focal onset seizures, generalised onset seizures
and overall adjusted by epilepsy type.
We determined the quality of the evidence using the GRADE ap-
proach (Schünemann 2013), where we downgraded evidence in
the presence of high risk of bias in at least one trial, indirectness
of the evidence, unexplained heterogeneity or inconsistency, im-
precision of results and high probability of publication bias. We
downgraded evidence by one level if the limitation was considered
serious and two levels if considered very serious, as judged by the
review authors.
R E S U L T S
Description of studies
Results of the search
We identified 334 records from the databases and search strategies
outlined in Electronic searches. We found no further records by
searching other resources. We removed 126 duplicate records and
screened 208 records (title and abstract) for inclusion in the review.
We excluded 178 records based on title and abstract and assessed
30 full-text articles for inclusion in the review. We excluded 19
studies from the review (see Excluded studies below) and included
11 trials in the review (see Included studies below). We updated
the searches in May 2015, resulting in 35 hits. We removed seven
duplicate records and screened 28 records (title and abstract); we
excluded all 28 records.
For the 2018 update of this review we identified 129 records from
the databases and search strategies outlined in Electronic searches.
We removed 21 duplicate records and screened 108 records (title
and abstract) for inclusion in the review. All 108 records were
clearly irrelevant and we excluded them.
See Figure 1 for PRISMA study flow diagram for the eligibility
screening of all studies identified in searches for all versions of this
review (previous searches and the most recent search in February
2018).
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Figure 1. Study flow diagram.
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Included studies
We included 11 trials in the review (Callaghan 1985; Czapinski
1997a; Craig 1994; De Silva 1996; Forsythe 1991; Heller 1995;
Ramsay 1992; Rastogi 1991; Shakir 1981; Thilothammal 1996;
Turnbull 1985). One trial was available in abstract form only (
Czapinski 1997a).
Four trials recruited individuals of all ages (Callaghan 1985;
Ramsay 1992; Rastogi 1991; Shakir 1981), three trials recruited
adults only (Czapinski 1997a; Heller 1995; Turnbull 1985), three
trials recruited children only (De Silva 1996; Forsythe 1991;
Thilothammal 1996), and one trial recruited elderly individuals
only (Craig 1994).
One trial recruited individuals with focal onset seizures only (
Czapinski 1997a), two trials recruited individuals with generalised
onset seizures only (Ramsay 1992; Thilothammal 1996), seven
trials recruited individuals with focal onset seizures and generalised
onset seizures (Callaghan 1985; Craig 1994; De Silva 1996; Heller
1995; Rastogi 1991; Shakir 1981; Turnbull 1985), and one trial
did not provide information on the seizure types of individuals
recruited (Forsythe 1991).
Nine trials recruited individuals with new onset seizures only (
Callaghan 1985; Craig 1994; Czapinski 1997a; De Silva 1996;
Forsythe 1991; Heller 1995; Ramsay 1992; Thilothammal 1996;
Turnbull 1985), 64% of individuals in one trial had new onset
seizures, while the remaining individuals had uncontrolled seizures
on current therapy (Shakir 1981), and one trial did not specify
whether individuals were newly diagnosed (Rastogi 1991). Seven
trials were conducted in Europe (Callaghan 1985; Craig 1994;
Czapinski 1997a; De Silva 1996; Forsythe 1991; Heller 1995;
Turnbull 1985), one trial in the USA (Ramsay 1992), two trials in
India (Rastogi 1991; Thilothammal 1996), and one trial in two
centres in Europe and New Zealand (Shakir 1981).
Individual participant data (IPD) were provided by trial authors
for five trials which recruited a total of 669 participants, represent-
ing 60% of individuals from all 1119 eligible participants iden-
tified in eligible trials (Craig 1994; De Silva 1996; Heller 1995;
Ramsay 1992; Turnbull 1985). Data were converted from paper
format to computer datasets in two trials (Ramsay 1992; Turnbull
1985), computerised datawere provideddirectly in one trial (Craig
1994), and a combinationof both (althoughmostly computerised)
were supplied by the authors of two trials (De Silva 1996; Heller
1995).
Data were available for the following participant characteris-
tics (percentage of participants with data available): seizure type
(100%); gender (99.6%) age at randomisation (99.3%); number
of seizures in the six months prior to randomisation (79%); and
epilepsy duration (i.e. time since first seizure to randomisation,
73%). Electroencephalographic (EEG) data had been recorded for
all five trials, but only computerised in two trials (Craig 1994;
Turnbull 1985). Similar difficulties were encountered with com-
puterised tomography/magnetic resonance imaging (CT/MRI)
data available for only one trial (Turnbull 1985), and neurological
examination findings, available for only two trials (De Silva 1996;
Heller 1995). See the Characteristics of included studies tables,
Table 1 and Table 2 for further details.
IIPD were not provided for the remaining six of these trials
(Callaghan 1985; Czapinski 1997a; Forsythe 1991; Rastogi 1991;
Shakir 1981;Thilothammal 1996), inwhich a total of 450 individ-
uals had been randomised to either phenytoin or valproate. Suffi-
cient participant level data were presented in the trial publications
of Forsythe 1991 and Shakir 1981 to include these studies within
the analysis of ’time to treatment failure’ (see Data extraction and
management and Effects of interventions). We could not extract
sufficient aggregate data from the trial publication in any other
trial, or for any other outcomes to include in data synthesis. Full
details of outcomes considered and a summary of results of each
trial for which IPD were not available to us can be found in Table
3.
Excluded studies
We excluded 14 duplicate trials (Berg 1993; Callaghan 1981;
Callaghan 1983; Callaghan 1984; Craig 1993; Czapinski 1997b;
Czapinski 1997c; Goggin 1984; Goggin 1986; Shakir 1980; Tallis
1994a; Tallis 1994b; Turnbull 1982; Wilder 1983), and we re-
tained the most relevant primary reference for each trial in the re-
view. One trial was not randomised (Zeng 2010), and four did not
make a randomised comparison between valproate and phenytoin
(Jannuzzi 2000; Kaminow 2003; Sabers 1995; Schmidt 2007; see
Characteristics of excluded studies for detailed reasons for exclu-
sion).
Risk of bias in included studies
For further details see Characteristics of included studies, Figure
2 and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
(1) Trials for which individual participant data (IPD) were
provided
Three trials reported adequate methods of randomisation and al-
location concealment; two trials used permuted blocks to gener-
ate a random list and concealed allocation by using sealed opaque
envelopes (De Silva 1996; Heller 1995). One trial used a com-
puter minimisation programme and a pharmacy-controlled allo-
cation (Craig 1994); we judged these trials to be at low risk of bias
for random sequence generation and allocation concealment. One
trail reported that random number tables were used but did not
report sufficient information about methods of allocation conceal-
ment (Ramsay 1992). One trial did not report sufficient informa-
tion about methods of randomisation and allocation concealment
(Turnbull 1985).
(2) Trials for which no IPD were available
Two trials reported adequatemethods of randomisation: telephone
randomisation in Shakir 1981, and a computer-generated list of
randomised numbers in Thilothammal 1996; we judged these
studies at low risk of bias for random sequence generation. Two
trials reported no information on methods of randomisation (
Czapinski 1997a; Rastogi 1991) (unclear risk of bias), one trial
reported unclear information on randomisation (Callaghan 1985)
(unclear risk of bias), and one trial reported an inadequate method
of randomisation, i.e. quota allocation (Forsythe 1991) (high risk
of bias). We judged five of the six trials to be at unclear risk of
bias as they reported no information on allocation concealment
(Czapinski 1997a; Forsythe 1991; Rastogi 1991; Shakir 1981;
Thilothammal 1996), andone trial at high risk of bias as it reported
an inadequate method of allocation concealment based on ’drug
of first preference’ (Callaghan 1985).
Blinding
(1) Trials for which IPD were provided
One trial was single-blinded (outcome assessor for cognitive test-
ing) (Craig 1994) (low risk of bias), three trials were unblinded
for “practical and ethical reasons” (De Silva 1996; Heller 1995;
Ramsay 1992) (high risk of bias), and one trial provided no infor-
mation on blinding (Turnbull 1985) (unclear risk of bias).
(2) Trials for which no IPD were available
One trial was described as double-blinded (Thilothammal 1996)
but it was unclear who was blinded, one trial was single-blinded
(outcome assessor for cognitive testing) (Forsythe 1991), and
no information was provided on blinding in the other trials
(Callaghan 1985; Czapinski 1997a; Rastogi 1991; Shakir 1981).
Incomplete outcome data
(1) Trials for which IPD were provided
In theory, a review using IPD should overcome issues of attrition
bias, as unpublished data can be provided, unpublished outcomes
calculated and all randomised participants can be analysed by an
intention-to-treat approach. All five trials reported attrition rates
and provided IPD for all randomised individuals (Craig 1994;
De Silva 1996; Heller 1995; Ramsay 1992; Turnbull 1985); we
judged all five trials at low risk of attrition bias.
(2) Trials for which no IPD were available
Four trials reported attrition rates and analysed all randomised par-
ticipants using an intention-to-treat approach (Callaghan 1985;
Forsythe 1991; Shakir 1981; Thilothammal 1996); low risk of at-
trition bias. Two trials did not provide sufficient information to
assess attrition bias (Czapinski 1997a; Rastogi 1991); unclear risk
of attrition bias.
Selective reporting
The authors of Craig 1994 provided a protocol; the outcomes
specified in the protocol were consistent with the outcomes re-
ported in the publication, and we therefore judged the risk of se-
lective reporting bias to be low. Protocols were not available for
any of the other 10 included trials so we made a judgement of the
risk of bias based on the information included in the publications
(see Characteristics of included studies for more information). We
judged eight of the other 10 studies at low risk of reporting bias;
Czapinski 1997a and Forsythe 1991 were judged at unclear risk
of reporting bias.
(1) Trials for which IPD were provided
In theory, a review using IPD should overcome issues of reporting
biases, as unpublished data can be provided and unpublished out-
comes calculated. Sufficient IPD were provided to calculate the
four outcomes: ’time to treatment failure’, ’time to achieve six-
month remission’, ’time to achieve 12-month remission’ and ’time
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to first seizure’ for four of the five trials (De Silva 1996; Heller
1995; Ramsay 1992; Turnbull 1985). Treatment failure informa-
tion was not provided for one trial (Craig 1994), so we could not
calculate ’time to treatment failure’, but we had sufficient infor-
mation to calculate the other three outcomes.
(2) Trials for which no IPD were available
Seizure outcomes and adverse events were well reported in four
trials (Callaghan 1985; Rastogi 1991; Shakir 1981; Thilothammal
1996); low risk of reporting bias. One trial reported cognitive
outcomes and adverse events, but no seizure outcomes (Forsythe
1991); however as no protocol was available for this trial we do
not know whether seizure outcomes were planned a priori, and
we judged this trial at unclear risk of reporting bias. One trial was
in abstract form only and did not provide sufficient information
to assess selective reporting bias (Czapinski 1997a); also judged at
unclear risk of reporting bias.
Other potential sources of bias
We detected no other potential sources of bias in any of the 10 of
the 11 trials included in the review, however limited information
was available for Czapinski 1997a which was only available as an
abstract so we judged this trial to be at unclear risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison Sodium
valproate compared with phenytoin monotherapy for epilepsy
(primary outcome); Summary of findings 2 Sodium valproate
compared with phenytoin monotherapy for epilepsy (secondary
outcomes)
A summary of the outcomes reported in trials for which no IPD
were available are reported in Table 3.
See Table 4 for details regarding the number of individuals (with
IPD) contributing to each analysis, Summary of findings for the
main comparison for a summary of the results for the primary out-
come ’time to treatment failure’ (stratified by epilepsy type), and
Summary of findings 2 for a summary of results for the secondary
outcomes ’time to first seizure’ and ’time to 12-month remission’.
Survival curve plots are shown in Figure 4; Figure 5; Figure 6;
Figure 7; Figure 8; Figure 9; Figure 10; Figure 11; Figure 12; Figure
13; Figure 14 and Figure 15 . All survival curve plots were pro-
duced in Stata software version 14 (Stata 2015). using data from
all trials providing IPD combined.
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Figure 4. Time to treatment failure - any reason related to the treatment (PHT: phenytoin; SV: sodium
valproate)
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Figure 5. Time to treatment failure - any reason related to the treatment, by epilepsy type (PHT:
phenytoin; SV: sodium valproate)
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Figure 6. Time to treatment failure due to adverse events (PHT: phenytoin; SV: sodium valproate)
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Figure 7. Time to treatment failure due to adverse events, by epilepsy type (PHT: phenytoin; SV: sodium
valproate)
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Figure 8. Time to treatment failure due to lack of efficacy (PHT: phenytoin; SV: sodium valproate)
22Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 9. Time to treatment failure due to lack of efficacy, by epilepsy type (PHT: phenytoin; SV: sodium
valproate)
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Figure 10. Time to first seizure (PHT: phenytoin; SV: sodium valproate)
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Figure 11. Time to first seizure - by epilepsy type. (PHT: phenytoin; SV: sodium valproate)
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Figure 12. Time to achieve 12-month remission (PHT: phenytoin; SV: sodium valproate)
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Figure 13. Time to achieve 12-month remission - by epilepsy type. (PHT: phenytoin; SV: sodium valproate)
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Figure 14. Time to achieve six-month remission (PHT: phenytoin; SV: sodium valproate)
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Figure 15. Time to achieve six-month remission (PHT: phenytoin; SV: sodium valproate)
We note that participants with event times of zero (i.e. those who
experienced treatment failure or experienced seizure recurrence on
the day of randomisation) are not included in the ’numbers at risk’
on the graphs and that data is not stratified by trial within these
survival curve plots. All figures are intended to provide a visual
representation of outcomes, extent of follow-up and visual dif-
ferences between seizure types. These graphs are not intended to
show statistical significance and numerical values may vary com-
pared to the text due to differences in methodology.
We calculated all HRs presented below by generic inverse variance
fixed-effect meta-analysis unless otherwise stated. All analyses met
the assumption of proportional hazards (the addition of a time-
varying covariate into the model was non-significant).
Primary outcome
Time to treatment failure (retention time)
For this outcome, a HR less than one indicates a clinical advantage
for valproate.
Time to treatment failure and reason for treatment withdrawal or
treatment failure were available for 495 individuals from four trials
(De Silva 1996; Heller 1995; Ramsay 1992; Turnbull 1985); 74%
of individuals from five trials providing IPD (44% of all 1119
eligible individuals). Treatment failure data were not available for
the fifth trial (Craig 1994). Sufficient IPDwere available in the trial
publications for a further 74 individuals from two trials (Forsythe
1991; Shakir 1981). Therefore, a total of 569 individuals (51% of
1119 eligible individuals) from six trials could contribute to the
analysis of this outcome.
Reasons for premature discontinuation of treatment (treatment
failure) were provided for 571 participants in the six trials (reasons
for treatment failure but no date of treatment failure provided for
two participants). See Table 5 for reasons for premature termina-
tion of the study by treatment and how we classified these reasons
in analysis.
Out of 571 participants for whom we had reasons for treatment
failure orwithdrawal, 243participants prematurelywithdrew from
treatment (43%): 122 out of 300 (41%) participants randomised
to valproate and 121 out of 271 (45%) participants randomised
to phenytoin.
We deemed 138 participants (57% of total treatment failures) to
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have withdrawn for reasons related to the allocated drug: 69 (57%
of treatment failures) on valproate and 69 (57% of treatment fail-
ures) on phenytoin and we classified these reasons as ’events’ in the
analysis. The most common treatment-related reasons for treat-
ment failure were lack of efficacy: 54 withdrawals (22% of total
treatment failures), 28 (23% of total treatment failures) on val-
proate and 26 (21% of total treatment failures) on phenytoin; and
adverse events: 42 withdrawals (17% of total treatment failures),
16 (13% of total treatment failures) on valproate and 26 (21% of
total treatment failures) on phenytoin.
We classed the other 105 reasons (53 on valproate and 52 on
phenytoin), which were mostly withdrawal from treatment due to
seizure remission (64% of other withdrawals), to be not related
to the treatment and censored these participants in the analysis,
in addition to the 328 participants (178 on valproate and 150 on
carbamazepine) who completed the trial without withdrawing or
failing treatment.
Considering time to treatment failure for any reason related to the
treatment, the overall pooled HR (for 569 participants providing
IPD from 6 trials) was 0.94 (95% confidence interval (CI) 0.67
to 1.32, P = 0.17; moderate-quality evidence) indicating no clear
advantage for either drug (Analysis 1.1). No important hetero-
geneity was present between trials (I2= 15%).
Considering time to treatment failure due to adverse events (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), 495 participants provided IPD from four trials;
no participants withdrew from one or both of the drugs due to
lack of efficacy in two of the trials (Forsythe 1991; Shakir 1981,
see Table 5). The overall pooled HR was 0.68 (95% CI 0.40 to
1.17, P = 0.16; moderate-quality evidence) which suggests a slight
advantage towards valproate (i.e. a suggestion that treatment fail-
ures due to adverse events may occur later on valproate than on
phenytoin), but this is not statistically significant (Analysis 1.2).
A substantial amount of heterogeneity was present between trials
(I2= 67%) and when analysis is repeated with random-effects, the
CIs of the pooled HR are substantially wider 0.75 (95% CI 0.28
to 1.98). This heterogeneity is investigated further in subgroup
analysis by epilepsy type below.
Considering time to treatment failure due to lack of efficacy (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), the overall pooled HR (for 569 participants
providing IPD from 6 trials) was 1.23 (95% CI 0.77 to 1.97, P
= 0.38; moderate-quality evidence) which suggests a slight advan-
tage towards phenytoin (i.e. a suggestion that treatment failures
due to lack of efficacy may occur later on phenytoin than on val-
proate), but this is not statistically significant (Analysis 1.3). No
heterogeneity was present between trials (I2= 0%).
Subgroup analyses: epilepsy type (focal versus generalised
onset)
Treatment failure data for 41 participants extracted from Forsythe
1991 did not distinguish between epilepsy type (focal onset or
generalised onset) and therefore could not be included in themeta-
analysis stratified by epilepsy type.
Considering time to treatment failure for any reason related to
the treatment, the overall pooled HR (adjusted by epilepsy type
for 528 participants from 5 trials) was 0.88 (95% CI 0.61 to
1.27, P = 0.51, I2= 29%;moderate-quality evidence; Analysis 1.4).
This result is similar to the unadjusted pooled HR (Analysis 1.1),
and conclusions remain unchanged following the exclusion of 41
individuals in the stratified analysis (Forsythe 1991).
For individuals with generalised onset seizures (341 participants
from 5 trials), the pooled HR was 0.94 (95% CI 0.55 to 1.61, P
= 0.82, I² = 59%; low-quality evidence), indicating no clear ad-
vantage for either drug. For individuals with focal onset seizures
(187 participants from 4 trials), the pooled HR was 0.83 (95%
CI 0.50 to 1.38, P = 0.48, I² = 0%; moderate-quality evidence),
suggesting a slight advantage for valproate which is not statisti-
cally significant. There was no evidence of an interaction between
epilepsy type (focal onset versus generalised onset) and treatment
effect (Chi² = 0.10, df = 1, P = 0.75, I² = 0%; Analysis 1.4).
A large amount of heterogeneity was present between trials within
the generalised onset seizure subgroup (I² = 59%) and when anal-
ysis is repeated with random-effects, the CIs of the pooled HR
become much wider: 0.93 (95% CI 0.37 to 231). On visual in-
spection of the forest plot (see Analysis 1.4), one trial appears to
be the source of this variability (Heller 1995), as this trial shows
a large statistically significant treatment effect in favour of pheny-
toin, while the other four trials show general non-significant re-
sults, mostly in favour of valproate (De Silva 1996; Ramsay 1992;
Shakir 1981; Turnbull 1985). Additionally, this heterogeneitymay
be due to misclassification of epilepsy type (specifically where gen-
eralised onset seizures have been incorrectly classified); this is in-
vestigated further in sensitivity analysis below.
Considering time to treatment failure due to adverse events, no in-
dividualswithdrew fromeither drugdue to adverse events in Shakir
1981 so this trial is not included in this analysis and no individ-
uals with generalised onset seizures withdrew from valproate due
to adverse events in Turnbull 1985 so this epilepsy type subgroup
was not included in this analysis. The overall pooledHR (adjusted
by epilepsy type for 418 participants from 4 trials) was 0.77 (95%
CI 0.44 to 1.37, P = 0.38, I2=37%; moderate-quality evidence;
Analysis 1.5). This result is similar to the unadjusted pooled HR
(Analysis 1.2), and conclusions remain unchanged following the
exclusion of participants from Shakir 1981 and Turnbull 1985.
For individuals with generalised onset seizures (250 participants
from 3 trials), the pooled HR was 0.75 (95% CI 0.35 to 1.60, P
= 0.46, I² = 71%; low-quality evidence), suggesting a slight ad-
vantage for valproate which is not statistically significant. For in-
dividuals with focal onset seizures (168 participants from 3 trials),
the pooled HR was 0.81 (95% CI 0.34 to 1.90, P = 0.62, I² =
0%; moderate-quality evidence), again suggesting a slight advan-
tage for valproate which is not statistically significant. There was
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no evidence of an interaction between epilepsy type (focal onset
versus generalised onset) and treatment effect (Chi² = 0.02, df =
1, P = 0.90, I² = 0%; Analysis 1.5).
Again, a large amount of heterogeneity was present between tri-
als within the generalised onset seizure subgroup (I² = 71%), and
when analysis is repeated with random-effects, the CIs of the
pooled HR are substantially wider 1.15 (95% CI 0.21 to 6.23).
This variability may also originate from fairly small numbers of
individuals with generalised seizures failing treatment due to ad-
verse events (see Table 5), or similarly to the analysis of ’time to
treatment failure’ for any reason related to treatment, this may be
due to potential misclassification of epilepsy type; this is investi-
gated further in sensitivity analysis below.
Considering time to treatment failure due to lack of efficacy, no
individuals with generalised onset seizures withdrew from either
drug due to lack of efficacy in Turnbull 1985 so this epilepsy type
subgroup was not included in this analysis. The overall pooledHR
(adjusted by epilepsy type for 451 participants from 5 trials) was
1.16 (95% CI 0.71 to 1.89, P = 0.55, I2=0%; moderate-quality
evidence; Analysis 1.6). This result is similar to the unadjusted
pooled HR (Analysis 1.3), and conclusions remain unchanged
following the exclusion of participants from Turnbull 1985.
For individuals with generalised onset seizures (264 participants
from 4 trials), the pooled HR was 1.51 (95% CI 0.66 to 3.45, P
= 0.33, I² = 23%; low-quality evidence), suggesting a slight ad-
vantage for phenytoin which is not statistically significant. For in-
dividuals with focal onset seizures (187 participants from 4 tri-
als), the pooled HR was 1.01 (95% CI 0.55 to 1.85, P = 0.98, I²
= 0%; moderate-quality evidence), indicating no clear advantage
for either drug. There was no evidence of an interaction between
epilepsy type (focal onset versus generalised onset) and treatment
effect (Chi² = 0.60, df = 1, P = 0.44, I² = 0%; Analysis 1.6). No
important heterogeneity was present in overall analysis or within
epilepsy type subgroups (I2 < 25% for all analyses).
Sensitivity analysis
Sensitivity analyses were conducted to investigate misclassification
of seizure type, reclassifying up to 100 individuals from four trials
(Heller 1995; Ramsay 1992; Shakir 1981; Turnbull 1985) aged 30
or older with new onset generalised seizures to focal onset seizures
or an uncertain seizure type. The results of the two sensitivity
analyses are shown in Table 6.
For all three treatment failure outcomes: time to treatment failure
for any reason related to treatment; due to adverse events; and
due to lack of efficacy, sensitivity analyses in which individuals
classified as experiencing generalised onset seizures and age at onset
> 30 years reclassified as experiencing focal onset seizures, show
numerically similar results and conclusions remain unchanged.
There was no evidence of an association between epilepsy type and
treatment effect following reclassification for any of the treatment
failure outcomes
Sensitivity analysis in which individuals classified as experiencing
generalised onset seizures and age at onset > 30 years were reclas-
sified as experiencing uncertain seizure type was performed only
for time to treatment failure for any reason related to treatment.
In the sensitivity analysis of ’time to treatment failure for any rea-
son related to treatment’ in which individuals classified as experi-
encing generalised onset seizures and age at onset > 30 years were
reclassified as uncertain seizure type, a large, but non-significant
advantage for phenytoin was shown in the uncertain seizure type
group: (pooled HR 6.83, 0.82 to 57.16), which was substantially
different in the direction of effect from estimates for the ’focal
onset seizures’ subgroup (pooled HR 0.83, 95% CI 0.50 to 1.38),
and ’generalised onset seizures’ groups (pooled HR 0.77, 95% CI
0.42 to 1.41), both indicating a non-significant advantage for val-
proate. There was, however, still no evidence of an association be-
tween epilepsy type and treatment effect in this analysis (Chi² =
3.80, df = 2; (P = 0.15), I² = 47.3%) and the result within the un-
certain seizure type group should be interpreted with caution due
to relatively small numbers of individuals with uncertain seizure
types failing treatment in each trial.
The sensitivity analysis could not be performed for ’time to treat-
ment failure due to adverse events’ or ’due to lack of efficacy’ due
to very small numbers of participants failing treatment for these
reasons in the uncertain epilepsy type groups in each trial.
Heterogeneity present within analyses for individuals with gen-
eralised onset seizures (see Analysis 1.4 and Analysis 1.5), does
not seem to be explained by the potential misclassification of
seizure type; therefore results for individuals with generalised on-
set seizures should be interpreted with caution due to this unex-
plained inconsistency in results.
Secondary outcomes
Time to first seizure post-randomisation
For this outcome, a HR less than one indicates a clinical advantage
for valproate.
Data for 639 individuals (96% of those providing IPD) from five
trials were available for the analysis of this outcome. Seizure recur-
rence occurred in 371 out of 639 participants (58%), 189 out of
333 (57%) on valproate and 181 out of 306 (59%) on phenytoin.
The overall pooled HR (for 639 participants) was 1.04 (95% CI
0.85 to 1.28, P = 0.70; low-quality evidence) indicating no clear
advantage for either drug. There was no important statistical het-
erogeneity between trials (I² = 5%; Analysis 1.7).
Subgroup analyses: epilepsy type (focal versus generalised
onset)
For individuals with generalised seizures (395 participants from
5 trials), the pooled HR was 0.97 (95% CI 0.72 to 1.30, P =
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0.82; low-quality evidence), indicating no clear advantage for ei-
ther drug. For individuals with focal onset seizures (244 partici-
pants from 4 trials), the pooled HR was 1.20 (95% CI 0.90 to
1.60, P = 0.22; low-quality evidence), suggesting an advantage
for phenytoin (i.e. that first seizure recurrence may occur later on
phenytoin compared to valproate), but this advantage is not sta-
tistically significant. Overall, the pooled HR (adjusted for seizure
type for 639participants)was 1.08 (95%CI 0.88 to 1.33, P = 0.47;
low-quality evidence), suggesting a slight advantage for phenytoin
which is not statistically significant. There was no evidence of an
interaction between epilepsy type (focal onset versus generalised
onset) and treatment effect (Chi² = 1.06, df = 1 (P = 0.30), I² =
5.6%) and no heterogeneity was present in any analysis (I² = 0%;
Analysis 1.8).
Sensitivity analysis
A sensitivity analysis including generalised seizures of all types dur-
ing follow-up (only recorded in Ramsay 1992), produced the fol-
lowing results: for individuals with generalised seizures, the pooled
HR was 0.95 (95% CI 0.71 to 1.27, P = 0.74), indicating no
clear advantage for either drug. For individuals with focal onset
seizures, the pooled HR was unchanged: 1.20 (95% CI 0.90 to
1.60, P = 0.22), suggesting an advantage for phenytoin which is
not statistically significant. Overall, the pooled HR (adjusted for
seizure type) was 1.08 (95%CI 0.86 to 1.32, P = 0.49), suggesting
an advantage for phenytoin which is not statistically significant.
Numerical results are very similar to those presented in Analysis
1.7 and Analysis 1.8 and overall conclusions are unchanged, there-
fore, results for time to first seizure (post-randomisation) seem ro-
bust to the exclusion of other generalised seizure types (other than
generalised tonic-clonic seizures) in Ramsay 1992.
Sensitivity analyses were conducted to investigate misclassification
of seizure type, reclassifying 171 individuals from four trials (Craig
1994;Heller 1995; Ramsay 1992; Turnbull 1985) aged 30 or older
with new onset generalised seizures to focal onset seizures or an
uncertain seizure type. The results of the two sensitivity analyses
are shown in Table 6.
Within both of the sensitivity analyses, following reclassification,
an association between epilepsy type and treatment effect is sug-
gested. For generalised seizures, and age of onset > 30 years re-
classified as ’focal onset seizures’, the result of the test for sub-
group differences is statistically significant: Chi² = 5.46, df = 1 (P
= 0.02), I² = 81.7% (Analysis 1.9). Within the focal onset seizure
group, a non-significant advantage to phenytoin is suggested: 1.23
(9% CI (0.96 to 1.57, P = 0.09), while in the generalised on-
set seizure group, a non-significant advantage to valproate is sug-
gested: pooled HR 0.72 (95% CI 0.50 to 1.05, P = 0.09); al-
though neither result is statistically significant, the observed direc-
tions of effect within this sensitivity analysis was anticipated a pri-
ori (see How the intervention might work and Subgroup analysis
and investigation of heterogeneity).
For generalised seizures, and age of onset > 30 years reclassified
as ’uncertain seizure type’, the result of the test for subgroup dif-
ferences is not statistically significant, but subgroup analysis does
suggest some potential differences between the epilepsy type sub-
groups: Chi² = 5.79, df = 2 (P = 0.06), I² = 65.5% (Analysis 1.10).
The direction of effect for the ’uncertain seizure type’ subgroup
(pooled HR 1.35, 95% CI 0.85 to 2.14; P = 0.22) is similar to
that of the ’focal onset’ subgroup (pooled HR 1.20, 95% CI 0.90
to 1.60; P = 0.22), both indicating a non-significant advantage
for phenytoin and also suggesting that these individuals with ’un-
certain’ seizure types (who were originally classified as experienc-
ing generalised onset seizures) are actually experiencing focal on-
set seizures. Furthermore, valproate now appears more effective
in generalised onset seizures (pooled HR 0.72, 95% CI 0.50 to
1.05; P = 0.09) when compared to the original analysis (Analysis
1.8; Analysis 1.10). Again, although neither result is statistically
significant, the observed directions of effect within this sensitivity
analysis were anticipated a priori (see How the intervention might
work and Subgroup analysis and investigation of heterogeneity).
Therefore, due to the potential impact of any misclassification
of epilepsy type on the numerical results and conclusions for the
outcome, ’time to first seizure’, results of Analysis 1.7, Analysis 1.8,
Analysis 1.9 and Analysis 1.10 should be interpreted with caution.
Time to achieve 12-month remission (seizure-free period)
For this outcome, a HR less than one indicates a clinical advantage
for phenytoin.
Data for 514 individuals (77% of those providing IPD) from four
trials were available for the analysis of this outcome (Craig 1994;
De Silva 1996; Heller 1995; Turnbull 1985; see Table 4). Indi-
viduals were only followed up for six months in the fifth trial
(Ramsay 1992), which could not contribute data to this outcome.
Twelve-month remission was achieved by 302 out of 514 partici-
pants (59%); 147 out of 256 (57%) on valproate and 155 out of
258 (60%) on phenytoin. The overall pooledHR (for 514 partici-
pants) was 1.03 (95%CI 0.82 to 1.29, P = 0.80; moderate-quality
evidence), indicating no clear advantage to either drug. There is
no evidence of statistical heterogeneity between trials (I² = 0%;
Analysis 1.11).
Subgroup analyses: epilepsy type (focal versus generalised
onset)
For individuals with generalised seizures (270 participants from
4 trials), the pooled HR was 0.96 (95% CI 0.71 to 1.29, P =
0.79; moderate-quality evidence), indicating no clear advantage
for either drug. For individuals with focal onset seizures (244 par-
ticipants from 4 trials), the pooled HR was 1.11 (95% CI 0.78
to 1.60, P = 0.56; moderate-quality evidence), indicating a slight
advantage for valproate ((i.e. that 12-month remission may occur
slightly earlier on valproate than phenytoin), but this advantage
32Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
is not statistically significant. Overall, the pooled HR (adjusted
for epilepsy type for 514 participants) was 1.02 (95% CI 0.81 to
1.28, P = 0.87; moderate-quality evidence), suggesting no clear
clinical advantage for either drug. There was no evidence of an
interaction between epilepsy type (focal onset versus generalised
onset) and treatment (Chi² = 0.39, df = 1, P = 0.53, I² = 0%) and
no heterogeneity was present in any analysis (I² = 0%; Analysis
1.12).
Sensitivity analysis
Sensitivity analyses were conducted to investigate misclassification
of seizure type, reclassifying 145 individuals from three (Craig
1994; Heller 1995; Turnbull 1985) aged 30 or older with new
onset generalised seizures to focal onset seizures or an uncertain
seizure type. The results of the two sensitivity analyses are shown
in Table 6.
Results are numerically similar for individuals with focal onset
seizures, individuals with generalised onset seizures and overall
for all participants; conclusions are unchanged and there is no
evidence of an association between epilepsy type and treatment
effect following reclassification.
Time to achieve six-month remission (seizure-free period)
For this outcome, a HR less than one indicates a clinical advantage
for phenytoin.
Data for 639 individuals (96% of those providing IPD) from five
trials were available for the analysis of this outcome (see Table
4). Six-month remission was achieved by 434 out of 639 partici-
pants (68%); 228 out of 333 (68%) on valproate and 206 out of
306 (67%) on phenytoin. The overall pooled HR (for 639 par-
ticipants) was 1.08 (95% CI 0.89 to 1.30, P = 0.44; moderate-
quality evidence), suggesting a slight advantage to valproate (i.e.
that six-month remission may occur slightly earlier on valproate
than phenytoin), but this advantage is not statistically significant.
There is no evidence of statistical heterogeneity between trials (I²
= 0%; see Analysis 1.13).
Subgroup analyses: epilepsy type (focal versus generalised
onset)
For individuals with generalised seizures (395 participants from 5
trials), the pooled HR was 1.08 (95% CI 0.84 to 1.38, P = 0.54;
moderate-quality evidence), suggesting an advantage for valproate
which is not statistically significant. For individuals with focal
onset seizures (244 participants from 4 trials), the pooled HR was
1.00 (95% CI 0.73 to 1.35, P = 0.98; moderate-quality evidence),
indicating no clear advantage for either drug. Overall, the pooled
HR(adjusted for epilepsy type for 639participants)was 1.05 (95%
CI 0.86 to 1.27, P = 0.64; moderate-quality evidence), suggesting
no clear advantage for either drug. There was no evidence of an
interaction between epilepsy type (focal onset versus generalised
onset) and treatment (Chi² = 0.16, df = 1, P = 0.69, I² = 0%) and
no heterogeneity was present in any analysis (I² = 0%; Analysis
1.14).
Sensitivity analyses
A sensitivity analysis including generalised seizures of all types
during follow-up (only recorded in Ramsay 1992) produced the
following results: for individuals with generalised seizures (395
participants from 5 trials), the pooled HR was 1.19 (95% CI
0.88 to 1.61, P = 0.26), suggesting an advantage for valproate,
which is not statistically significant. For individuals with focal
onset seizures (244 participants from 4 trials), the pooled HR was
unchanged: 1.00 (95% CI 0.73 to 1.35, P = 0.98), indicating no
clear advantage for either drug. Overall, the pooled HR (adjusted
for epilepsy type) was 1.09 (95% CI 0.88 to 1.37, P = 0.40),
suggesting an advantage for valproate, which is not statistically
significant.
By including information on other generalised seizure types in
the trial by Ramsay 1992, a very slightly greater advantage for
valproate emerges. However, as numerical results are similar to
those presented in Analysis 1.13 and Analysis 1.14 and overall
conclusions are unchanged, results for time to six-month remission
seem robust to the exclusion of other generalised seizure types
(other than generalised tonic-clonic seizures) in Ramsay 1992.
Sensitivity analyses were conducted to investigate misclassification
of seizure type, reclassifying 171 individuals from four trials (Craig
1994;Heller 1995; Ramsay 1992; Turnbull 1985) aged 30 or older
with new onset generalised seizures to focal onset seizures or an
uncertain seizure type. The results of the two sensitivity analyses
are shown in Table 6.
Results are numerically similar for individuals with focal onset
seizures, individuals with generalised onset seizures and overall
for all participants; conclusions are unchanged and there is no
evidence of an association between epilepsy type and treatment
effect following reclassification.
Incidence of adverse events
See Table 7 for details of all adverse event data provided in the
studies included in this review. It is difficult to summarise the
’most common’ adverse events overall across the 11 studies due to
the differences in methods and differences in the levels of detail in
the reporting of adverse event data across the studies. In summary,
the adverse events reported by two or more studies in this review
are the following.
For valproate:
• drowsiness/somnolence/sedation (reported by Callaghan
1985; Craig 1994; De Silva 1996; Ramsay 1992; Rastogi 1991);
• weight gain (reported by Callaghan 1985; Craig 1994;
Rastogi 1991; Shakir 1981);
• tremor (reported by Craig 1994; De Silva 1996; Ramsay
1992; Turnbull 1985);
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• alopecia/hair loss (reported by Craig 1994; Shakir 1981;
Turnbull 1985);
• dizziness/unsteadiness (reported by Craig 1994; Heller
1995; Ramsay 1992);
• skin allergy/rash (reported by Ramsay 1992; Thilothammal
1996); and
• gastrointestinal problems (reported by Rastogi 1991; Shakir
1981).
For phenytoin:
• gingival (gum) hypertrophy/hyperplasia (reported by
Callaghan 1985; Rastogi 1991; Thilothammal 1996);
• rash (reported by Callaghan 1985; Craig 1994; De Silva
1996; Ramsay 1992);
• ataxia (reported by Callaghan 1985; Rastogi 1991; Shakir
1981; Thilothammal 1996; Turnbull 1985);
• nausea (reported by Ramsay 1992; Thilothammal 1996);
• dizziness/unsteadiness (reported by Craig 1994; Ramsay
1992);
• nystagmus (reported by Craig 1994; Rastogi 1991;
Thilothammal 1996; Turnbull 1985);
• drowsiness/somnolence/sedation (reported by Craig 1994;
De Silva 1996; Ramsay 1992; Rastogi 1991; Thilothammal
1996); and
• tremor (reported by Ramsay 1992; Turnbull 1985).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Valproate compared with phenytoin monotherapy for epilepsy
Patient or population: adults and children with newly-onset focal onset or generalised tonic-clonic seizures
Settings: outpat ients
Intervention: sodium valproate
Comparison: phenytoin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenytoin Sodium valproate
Time to first seizure
(post- randomisation)
All participants
Range of follow-up: 0 to
4859 days
The median t ime to f irst
seizure post-randomi-
sat ion was 275 days in
the phenytoin group
The median t ime to f irst
seizure post-randomi-
sat ion was 267 days
(7 days shorter) in the
sodium valproate group
HR 1.08
(0.88 to 1.33)a
639
(5 studies)
⊕⊕©©
Lowb,c
HR < 1 indicates a clini-
cal
advantage for val-
proate
Time to first seizure
(post- randomisation)
Subgroup: focal onset
seizures
Range of follow-up: 0 to
4859 days
The median t ime to f irst
seizure post-randomi-
sat ion was 75 days in
the phenytoin group
The median t ime to f irst
seizure post-randomi-
sat ion was 41 days (34
days shorter) in the
sodium valproate group
HR 1.20
(0.90 to 1.60)
244
(4 studies)
⊕⊕©©
Lowb,c
HR < 1 indicates a clini-
cal
advantage for val-
proate
Time to first seizure
(post- randomisation)
Subgroup: generalised on-
set seizures (tonic-clonic
only)
Range of follow-up: 1 to
4520 days
The median t ime to f irst
seizure post-randomi-
sat ion was 572 days in
the phenytoin group
The median t ime to f irst
seizure post-randomi-
sat ion was 549 days
(23 days shorter) in the
sodium valproate group
HR 0.97
(0.72 to 1.30)
395
(5 studies)
⊕⊕©©
Lowb,c
HR < 1 indicates a clini-
cal
advantage for val-
proate
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Time to achieve 12-
month remission
(seizure- free period)
All participants
Range of follow-up: 5 to
4614 days
The median t ime to
achieve 12-month re-
m ission was 380 days
in the phenytoin group
The median t ime to
achieve 12-month re-
m ission was 386 days
(6 days longer) in the
sodium valproate group
HR 1.02
(0.81 to 1.28)
514
(4 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clini-
cal
advantage for pheny-
toin
Time to achieve 12-
month remission
(seizure- free period)
Subgroup: focal onset
seizures
Range of follow-up: 5 to
4614 days
The median t ime to
achieve 12-month re-
m ission was 575 days
in the phenytoin group
The median t ime to
achieve 12-month re-
m ission was 549 days
(26 days shorter) in the
sodium valproate group
HR 1.11
(0.78 to 1.60)
244
(4 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clini-
cal
advantage for pheny-
toin
Time to achieve 12-
month remission
(seizure- free period)
Subgroup: generalised on-
set seizures (tonic-clonic
only)
Range of follow-up: 7 to
4544 days
The median t ime to
achieve 12-month re-
m ission was 365 days
in the phenytoin group
The median t ime to
achieve 12-month re-
m ission was 366 days
(1 day longer) in the
sodium valproate group
HR 0.96
(0.71 to 1.29)
270
(4 studies)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clini-
cal
advantage for pheny-
toin
* Illustrat ive risks in the phenytoin and sodium valproate groups are calculated at the median t ime to f irst seizure or t ime to 12-month remission (i.e. the t ime to 50% of
part icipants experiencing a f irst seizure or 12 months of remission) within each group across all t rials. The relat ive ef fect (pooled HR) shows the comparison of ’t ime to f irst
seizure’ or ’t ime to 12-month remission’ between the treatment groups
Abbreviations: CI: conf idence interval; HR: hazard rat io.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aPooled HR for all part icipants adjusted for seizure type.
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bDowngraded once as risk of bias judged high for four unblinded studies (Craig 1994; De Silva 1996; Heller 1995; Ramsay
1992).
cDowngraded once due to applicability: as up to 49% in the 5 trials classif ied as experiencing generalised onset seizures
may have had their seizure type wrongly classif ied; sensit ivity analyses show misclassif icat ion has an impact on results and
conclusions.
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D I S C U S S I O N
Summary of main results
The results of this review do not demonstrate a statistically sig-
nificant effect in favour of either valproate or phenytoin for the
primary global outcome ’time to treatment failure for any reason
related to the treatment (retention time)’. This outcome is influ-
enced by both the relative efficacy of the two drugs, and differences
in tolerability and safety.
As a difference in efficacy in one directionmay be confounded by a
difference in tolerability in the other, it may not be surprising that
any estimated differences are small, yet when considering specific
reasons for treatment failure (adverse events or lack of efficacy), still
no statistically significant differences were found between the two
drugs. The confidence intervals for the treatment failure outcomes
are relatively wide; too wide to confirm equivalence and clinically
important differences have not been excluded, particularly when
results for generalised and focal onset seizure subgroups are ex-
amined. Furthermore, as at least three of the trials contributing
individual participant data (IPD) to this outcome were open-la-
bel, clinical preconceptions about the two treatments, such as that
valproate is more effective in generalised seizures, while phenytoin
is more effective in focal onset seizures, and lack of masking, may
have influenced the treatment failure rates of the two treatments.
Similarly for the secondary outcomes ’time to achieve 12-month
remission (seizure-free period)’, ’time to achieve six-month remis-
sion (seizure-free period)’, and ’time to first seizure’, although no
statistically significant differences were found between valproate
and phenytoin, the confidence intervals are too wide to confirm
equivalence.
Overall completeness and applicability of
evidence
We have gratefully received IPD for 669 individuals (60% of
individuals from all eligible trials) from the authors of five tri-
als, which included a comparison of phenytoin with valproate
for the treatment of epilepsy (Craig 1994; De Silva 1996; Heller
1995; Ramsay 1992; Turnbull 1985). However, 376 individu-
als (34%) from four relevant trials could not be included in any
analysis, as IPD were not available and outcomes of interest were
not reported in the published reports (Callaghan 1985; Czapinski
1997a; Rastogi 1991; Thilothammal 1996). Sufficient data for 74
individuals (6%)were published in two trials to contribute to anal-
ysis for the primary outcome ’time to treatment failure’ (Forsythe
1991; Shakir 1981), but insufficient data were available to include
these individuals in the analyses of other outcomes. Having to
exclude data for one-third of eligible participants due to lack of
IPD and insufficient reporting in study publications is likely to
impact on the applicability of the evidence, however it is difficult
to quantify exactly how large this impact could be.
We did not find evidence of an interaction between treatment and
seizure type in any analysis using the epileptic seizure types that
participants were classified with in the original analysis. This result
is surprising, given the strong clinical impression that valproate
is more effective in generalised onset seizures while phenytoin is
more effective in focal onset seizures.
It may well be that an interaction does not exist. Alternatively, it
may be that an interaction does exist but that our meta-analysis
may not have the statistical power needed to detect an interaction;
it must be understood that the confidence intervals around the
estimates are wide, and that these results do not exclude the pos-
sibility of important differences existing. Additionally, subgroup
analyses by epilepsy type show some inconsistent results, such as
for our primary outcome ’time to treatment failure for any reason
related to the treatment’, treatment effect estimates indicate a po-
tentially important advantage for valproate for focal onset seizures,
with no clear advantage for either drug for generalised tonic-clonic
seizures, which goes against current practice and belief. Further-
more, a substantial amount of statistical heterogeneity was present
in some analyses of ’time to treatment failure,’ particularly within
analyses of individuals with generalised onset seizures, which could
not be explained by sensitivity analyses.
The impression that valproate is better for generalised seizures may
derive from its effects on generalised seizures other than tonic-
clonic, but important differences could exist for absence and my-
oclonus seizure types. However, were this the case, we might have
expected to see a treatment-seizure type interaction for the out-
come ’time to treatment failure’, if treatment had failed or a fur-
ther drug added to combat other seizure types. We were unable
to investigate these seizure types in detail in this review as most of
the trials providing IPD did not record post-randomisation gen-
eralised seizure types other than tonic-clonic occurring post-ran-
domisation.
The results of the original trials, and hence this meta-analysis, may
have been confounded by classification bias, i.e. individuals with
generalised seizures may have been misclassified as having focal
onset seizures and vice versa. There is good evidence from our
three reviews in our series of pair-wise reviews for monotherapy
in epilepsy comparing carbamazepine to phenobarbitone, pheny-
toin and valproate that misclassification is indeed an important is-
sue in epilepsy trials (Marson 2000; Nolan 2016c; Nevitt 2017b).
Within our review, the most striking indication that misclassifi-
cation may be a problem is the classification of subjects in Craig
1994. In this trial, 95 out of 166 (56%) of the recruited individ-
uals were classified as having a generalised epilepsy, which seems
unlikely given that the individuals were newly diagnosed and over
the age of 60 (Malafosse 1994). It is also interesting to note that
Ramsay 1992 is the only trial in this review that attempted to re-
cruit only individuals with generalised tonic-clonic seizures, How-
ever, this trial recruited too few individuals to have the power
to detect a difference between valproate and phenytoin. In this
trial, for a subgroup of individuals with definite electroencephalo-
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graphic (EEG) changes to support a diagnosis of an idiopathic
generalised epilepsy, there appeared to be a greater (but not signif-
icant) advantage for valproate, compared to the trial population
overall. This could again be interpreted as supporting the potential
for misclassification, which in turn could confound an interaction
between treatment and seizure type.We were unable to test for the
effects of EEG changes on the interaction between treatment and
seizure type due to EEG data not being collected for all trials, and
even where it was available, it was not done in a uniform way. It is
likely that these trials were initiated before the publication of the
International League Against Epilepsy Classification of Epileptic
Syndromes in 1989 (Commission 1989), but they did use the
International League Against Epilepsy Classification of Epileptic
Seizures that was published in 1981 (Commission 1981), which
does allow individuals to be classified as those with focal onset or
generalised seizures. The age of onset distribution of individuals
classified as having generalised seizures indicates misclassification
is likely to have occurred in up to 188 out of 384 (49%) indi-
viduals classified as having generalised onset seizures. Our results,
based on reclassifying the 188 individuals, indicate that classifica-
tion bias is a potentially important confounder of the results of
this review, particularly the outcome ’time to first seizure’.
Finally, it should be mentioned that the preparation of valproate
used in the included trials may have influenced the results. The
trials conducted in the UK all used valproate (Epilim) (Craig
1994; De Silva 1996; Heller 1995; Turnbull 1985). Ramsay 1992,
conducted in the USA, used valproic acid (Depakene) which is
thought to cause more gastrointestinal side effects than prepara-
tions containing either a mixture of valproate and valproic acid,
or valproate alone. There is no evidence from RCTs to support
this, but there are some data from observational studies (Brasfield
1999; Cranor 1997; Wilder 1983a). Given that this meta-anal-
ysis, and a similar meta-analysis comparing valproate and carba-
mazepine have failed to find convincing evidence of differences in
effect between different drugs (Marson 2000), it seems unlikely
that differing preparations of the same drug are likely to have a
major effect.
Quality of the evidence
The five trials for which IPD were made available were of gen-
erally good quality, with all five trials describing adequate meth-
ods of randomisation, and Craig 1994, De Silva 1996 and Heller
1995 also describing adequate methods of allocation concealment.
However, none of the five trials described a method of blinding of
participants and personnel, and only one trial stated that cognitive
outcome assessors were blinded to treatment allocation, raising
the possibility of performance and detection bias (Craig 1994).
Three trials were designed as open-label for “practical and ethi-
cal reasons” (De Silva 1996; Heller 1995; Ramsay 1992); for ex-
ample, Ramsay 1992 stated that the side effects of the respective
drugs would “quickly unblind” the trial anyway. A further differ-
ence between the five trials was the population recruited; two tri-
als recruited adults of all ages (Heller 1995; Turnbull 1985), one
recruited children only (De Silva 1996), one recruited adults and
children (Ramsay 1992), and one recruited adults over the age of
60 only (Craig 1994).
As explained within Overall completeness and applicability of
evidence, misclassification of seizure type (classification bias) is
likely to have impacted upon the results of the outcome ’time
to first seizure’ and for treatment failure outcomes, unexplained
heterogeneity was present in analysis, following subgroup analysis
and sensitivity analysis (including reclassification of seizure type).
For the reasons outlined in this section,we judged the quality of the
evidence to be moderate to low for ’time to treatment failure’ due
to risk of detection bias and unexplained heterogeneity (Summary
of findings for the main comparison), and low/moderate for the
outcomes of ’time to first seizure’ and ’time to 12-month remission’
respectively, due to risk of detection bias and classification bias
(see Summary of findings 2).
Potential biases in the review process
Wewere able to include IPD up to 743 out of 1119 eligible partici-
pants (66%) from sevenout of 11 trials in this review in the analysis
of at least one outcome. Such an approach has many advantages,
such as allowing the standardisation of definitions of outcomes
across trials, and attrition and reporting biases are reduced as we
can perform additional analyses and calculate additional outcomes
from unpublished data. For the outcomes we used in this review
that are of a time-to-event nature, an IPD approach is considered
to be the ’gold standard’ approach to analysis (Parmar 1998).
For reasons outside of our control, we were unable to obtain or
extract any IPD for 376 participants (34%) from four trials for
inclusion in any outcomes of this review; it is difficult to quantify
whether the exclusion of at least 34% of eligible participants from
analyses is likely to have impacted on the conclusions of this review.
Finally, we made some assumptions in the statistical methodology
used in this review. Firstly, when we received only follow-up dates
and seizure frequencies, we used linear interpolation to estimate.
We are aware that an individual’s seizure patterns may be non-
linear; therefore for this reason, in addition to the reasons out-
lined in Overall completeness and applicability of evidence, we
recommend caution when interpreting the numerical results of
the seizure-related outcomes.
Agreements and disagreements with other
studies or reviews
No single trial has found convincing differences between valproate
and phenytoin with respect to seizure control or seizure type
(Callaghan 1985; Craig 1994; Czapinski 1997a; De Silva 1996;
Forsythe 1991; Heller 1995; Ramsay 1992; Rastogi 1991; Shakir
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1981; Thilothammal 1996; Turnbull 1985). However, confidence
intervals around estimates have been wide and equivalence cannot
be inferred. Furthermore, this systematic review and meta-analy-
sis has not found any statistically significant differences between
valproate and phenytoin for any of the outcomes measures. To our
knowledge, this is the only systematic review and meta-analysis
which compares valproate and phenytoin monotherapy for focal
onset seizures and generalised onset tonic-clonic seizures. A net-
work meta-analysis has been published (Nevitt 2017a), compar-
ing all direct and indirect evidence from phenytoin, valproate and
other standard and new antiepileptic drugs licensed formonother-
apy, and it also found no differences between valproate and pheny-
toin for the outcomes specified in this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of this systematic review do not provide any conclusive
evidence for or against the current practice of using valproate as
a first-line treatment for individuals with generalised onset tonic-
clonic seizures, andphenytoin asmonotherapy for individualswith
focal onset seizures. Guidelines currently recommend lamotrigine
and carbamazepine as a first-line treatment for focal onset seizures
(NICE 2012); the results of this review do not inform current
treatment policy.
Implications for research
Finding overall differences between these standard antiepileptic
drugs has proved elusive. If overall differences do exist across het-
erogeneous populations of individuals, such as those studied here,
those differences are likely to be small, and in order to be clinically
useful, future comparative antiepileptic drug trials will need to be
powered accordingly. It has been argued that future comparative
antiepileptic drug trials be powered to establish equivalence (Jones
1996), and therefore be capable of detecting what is considered to
be the smallest important clinical difference.
This review highlights the need for future antiepileptic drug
monotherapy trials that recruit individuals with specific epilepsy
syndromes, to be designed and powered to detect a difference be-
tween particular antiepileptic drugs. An approach likely to reflect
and inform clinical practice, as well as being statistically powerful,
would be to recruit heterogeneous populations for whom epilepsy
syndromes have been adequately defined, with testing for interac-
tion between treatment and epilepsy syndrome. In view of poten-
tial problems of misclassification, syndromes will have to be well
defined, with adequate checking mechanisms to ensure that clas-
sifications are accurate, and with a system to recognise uncertainty
surrounding epilepsy syndromes in individuals within trials.
Clinical uncertainty about seizure and syndrome classification is
often present at the time of diagnosis and initial treatment of
epilepsy, and significant numbers of individuals with newly diag-
nosed epilepsy cannot be classified (Bodensteiner 1988; Ottman
1993). Seizures may have been few and unwitnessed, and inves-
tigations are commonly unhelpful, but there is nevertheless no
doubt that seizures have occurred and should be treated. Thismost
commonly applies to tonic-clonic seizures that may be generalised
at onset, or which may be secondarily generalised. In any trial,
such unclassified individuals need to be clearly identified, because
if they are not they may confound interpretation of results for
well classified individuals. We need to know how to manage those
whose classification we find more difficult.
The choice of outcomes at the design stage of a trial and the pre-
sentation of the results of outcomes, particularly of a time-to-event
nature, require very careful consideration. While the majority of
trials of a monotherapy design record an outcome measuring effi-
cacy (seizure control) and an outcome measuring tolerability (ad-
verse events), there is little uniformity between the definition of
the outcomes and the reporting of the summary statistics related
to the outcomes (Nolan 2013a), making an aggregate data ap-
proach to meta-analysis in reviews of monotherapy trials impos-
sible. Where trial authors cannot or will not make IPD available
for analysis, we are left with no choice but to exclude a proportion
of relevant evidence from the review, which may impact upon the
interpretation of the results of the review and the applicability of
the evidence and conclusions. The International League Against
Epilepsy recommends that trials of a monotherapy design should
adopt a primary effectiveness outcome of time to treatment failure
(i.e. retention time) and should be of a duration of at least 48
weeks to allow for assessment of longer-term outcomes, such as
remission (ILAE 1998; ILAE 2006). If trials followed these rec-
ommendations, an aggregate data approach to meta-analysis may
be feasible, reducing the resources and time required from an IPD
approach.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Callaghan 1985
Methods Parallel study design, outpatient setting
Study conducted in Eire (Republic of Ireland)
Randomisation based on two Latin squares and the preference of drug for the participant
An independent person selected “drug of first preference” from randomisation list
Participants Adults and children with a minimum of 2 untreated generalised or focal seizures in the
6 months preceding the trial
Number randomised: PHT = 58; SV = 64
48 participants (39%) with focal epilepsy. 67 (55%) men
Age range: 5-71. Duration of treatment (range in months):3-48
Interventions Monotherapy with PHT or SV
Mean daily dose achieved: PHT: 5.4 mg/kg; SV: 15.6 mg/kg
Outcomes Seizure control:
excellent (complete freedom of seizures)
good (> 50% reduction in seizure frequency)
poor (< 50% reduction in seizure frequency)
Notes Outcomes chosen for this review were not reported. IPD not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation based on 2 Latin Squares
without stratification. The first, second and
third preference of drug for the participant
appears to have been taken into account
in the process. Unclear if assignment was
completely random
Allocation concealment (selection bias) High risk An independent person (department secre-
tary) selected the “drug of first preference”
from randomisation list on a sequential ba-
sis. Allocation not adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
Unclear risk No information provided
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Callaghan 1985 (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attirition rates reported. ITT approach
taken, all randomised participants analysed
Selective reporting (reporting bias) Low risk Primary outcomes (seizure control) and
secondary outcomes (side effects) reported
sufficiently. No protocol available, out-
comes for this review not reported
Other bias Low risk No other bias detected
Craig 1994
Methods Parallel study design
Study conducted in the UK
Participants randomised using computerised stratified minimisation programme by age
group, sex and seizure type
Allocation was pharmacy-controlled
The main investigator performing cognitive testing was blinded to allocation. Partici-
pants and personnel unblinded
Participants Participants over 60 years of age with newly onset seizures (1 or more generalised tonic-
clonic seizures or 2 or more focal seizures)
Number randomised: PHT = 81; SV = 85
80 participants (48%) with focal epilepsy, 71 (44%) men
Mean age (range): 78 (61-95 years). Range of follow-up: 1-20 months
Interventions Monotherapy with PHT or SV
Starting doses: PHT: 200 mg/day, SV: 400 mg/day
Median daily dose achieved: PHT 247 mg (range 175-275); SV: 688 mg (range 400-
1000)
Outcomes Psychological tests (cognitive function, anxiety and depression)
Adverse event frequency
Seizure control
Notes Trial paper reports on a subset of 38 participants. Full IPD set provided and used for
this review includes all 166 participants randomised in the trial. IPD provided for 3/4
outcomes of this review (’time to treatment failure’ not available)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised stratified minimisation pro-
gramme, stratified for age group, gender
and seizure type
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Craig 1994 (Continued)
Allocation concealment (selection bias) Low risk Pharmacy-controlled allocation, prescrip-
tion disclosed to general practitioner and
consultant
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The main investigator performing cogni-
tive testing was blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT analysis un-
dertaken with all randomised participants
from IPD (see footnote 2)
Selective reporting (reporting bias) Low risk All outcome measures reported in pub-
lished report or provided in IPD (see foot-
note 2)
Other bias Low risk No other bias detected
Czapinski 1997a
Methods 36-month randomised comparative trial
Parallel study design
Study conducted in Poland
Method of generation of random list and allocation concealment not stated
Participants Adults with newly diagnosed epilepsy
Number randomised: PHT = 30; SV = 30
100% focal epilepsy, age range: 18 to 40 years
Percentage men and range of follow-up not mentioned
Interventions Monotherapy with PHT or SV
Starting doses: PHT: 200 mg/day, SV: 600 mg/day. Dose achieved not stated
Outcomes Proportion achieving 24-month remission at 3 years
Exclusions after randomisation due to adverse events or no efficacy
Notes Abstract only. Outcomes chosen for this review were not reported. IPD pledged but not
received
Risk of bias
Bias Authors’ judgement Support for judgement
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Czapinski 1997a (Continued)
Random sequence generation (selection
bias)
Unclear risk Trial “randomised” but no further informa-
tion provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Exclusion rates” (interpreted as treatment
withdrawal rates) reported for all treatment
groups, no further information provided
Selective reporting (reporting bias) Unclear risk No protocol available and trial reported
only in abstract form; outcomes for this re-
view not available
Other bias Unclear risk Insufficient detail provided in abstract to
allow judgement
De Silva 1996
Methods Parallel study design, outpatient setting
Study conducted at two centres in the UK
Random list generated using random permuted blocks
Allocation concealed using sealed opaque envelopes
Unblinded
Participants Children with newly diagnosed epilepsy (2 or more untreated focal or generalised tonic-
clonic seizures in the 12 months preceding the trial)
Number randomised: PHT = 54; SV = 49
55 children (53%) with focal epilepsy. 52 (50%) boys
Mean age (range): 10 (3-16) years. Range of follow-up (months): 3-88
Interventions Monotherapy with PHT or SV
Median daily dose achieved: PHT: 175 mg/day, SV: 600 mg/day
Outcomes Time to first seizure recurrence after start of therapy
Time to 12-month remission from all seizures
Adverse events and treatment withdrawals due to adverse events
Notes IPD provided for all outcomes of this review
Risk of bias
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De Silva 1996 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list generated using per-
muted blocks of size 8 or 16 with stratifi-
cation for centre, seizure type and presence
of neurological signs
Allocation concealment (selection bias) Low risk Allocation concealed via 4 batches of sealed
opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded, authors state masking of treat-
ment would not be “practicable or ethical”
and would “undermine compliance”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded, authors state masking of treat-
ment would not be “practicable or ethical”
and would “undermine compliance”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk No other bias detected
Forsythe 1991
Methods Parallel study design, outpatient setting
Study conducted in the UK
Patients randomly allocated using quota allocation allowing for gender, age, seizure type
and current treatment
Outcome assessors were single-blinded for cognitive testing
Participants Children with at least 3 newly diagnosed generalised or focal seizures within a period of
6 months
Number randomised: PHT = 20; SV = 21
No information on epilepsy type, gender or range of follow-up
Age range: 5-14 years. Trial duration: 12 months
Interventions Monotherapy with PHT or SV
Mean dose achieved: PHT: 6.1 mg/day, SV: 25.3 mg/day
Outcomes Cognitive assessments
Summary of withdrawals from randomised drug
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Forsythe 1991 (Continued)
Notes Outcomes chosen for this review were not reported. IPD not available, but could be
constructed from the publication for the outcome ’time on allocated drug’ (without
stratification by seizure type)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quota allocation by gender, age, seizure
type and current treatment is an inadequate
randomisation method
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel and participants (and parents)
unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors single-blinded for cog-
nitive testing
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, results reported
and analysed for all participants ran-
domised and all who completed various
stages of follow-up
Selective reporting (reporting bias) Unclear risk Cognitive outcomes described in methods
section well reported in results section. Ad-
verse events reported, no seizure outcomes
reported and outcomes chosen for this re-
view not reported. No protocol available so
unclear if seizure outcomes were planned a
priori
Other bias Low risk No other bias detected
Heller 1995
Methods Parallel study design, outpatient setting
Study conducted at two centres in the UK
Random list generated using random permuted blocks
Allocation concealed using sealed opaque envelopes
Unblinded
Participants Adults with newly diagnosed epilepsy (2 or more untreated focal or generalised tonic-
clonic seizures in the 12 months preceding the trial)
Number randomised: PHT = 63; SV = 61
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Heller 1995 (Continued)
53 participants (43%) with focal epilepsy. 62 (48%) men
Mean age (range): 33 (14-72) years
Range of follow-up (months): 1-91
Interventions Monotherapy with PHT or SV
Median daily dose achieved: PHT: 300 mg/day, SV: 800 mg/day
Outcomes Time to first seizure recurrence after start of therapy
Time to 12-month remission from all seizures
Adverse events and treatment withdrawal due to adverse events
Notes IPD provided for all outcomes of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list generated using per-
muted blocks of size 8 or 16 with stratifi-
cation for centre, seizure type and presence
of neurological signs
Allocation concealment (selection bias) Low risk Allocation concealed via 4 batches of con-
cealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded, authors state masking of treat-
ment would not be “practical” and would
have “introduced bias due to a very large
drop-out rate”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded, authors state masking of treat-
ment would not be “practical” and would
have “introduced bias due to a very large
drop-out rate”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analyses from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk No other bias detected
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Ramsay 1992
Methods Parallel trial
Study conducted at 16 centres in the USA
Participants assigned via randomisation tables within each centre in a 2:1 ratio (SV:
PHT)
Method of allocation concealment not stated
Unblinded
Participants Participants with at least 2 newly diagnosed and previously untreated primary generalised
tonic-clonic seizures within 14 days of starting the trial
Number randomised: PHT = 50; SV = 86
0% participants with focal epilepsy, 73 (54%) men
Mean age (range): 21 (3-64 years). Participants followed up for up to 6 months
Interventions Monotherapy with PHT or SV
Starting doses PHT: 3-5 mg/kg/day, SV: 10-15 mg/kg/day, doses gradually increased
Doses achieved not stated
Outcomes Time to first generalised tonic-clonic seizure
6-month seizure recurrence rates
Adverse events
Notes IPD provided for 3/4 outcomes of this review (maximum follow-up 6 months, therefore
trial cannot contribute to outcome ’time to achieve 12-month remission’)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised on a 2:1 ratio SV:
PHT using randomisation tables in each
centre (information provided by trial au-
thor)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial; authors state that differ-
ences in adverse events of PHT and SV
would “quickly unblind” the trial anyway
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial; authors state that differ-
ences in adverse events of PHT and SV
would “quickly unblind” the trial anyway
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
54Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ramsay 1992 (Continued)
Other bias Low risk No other bias detected
Rastogi 1991
Methods Parallel study design, outpatient setting
Study conducted in Meerut, India
No information provided on method of generation of random list, allocation conceal-
ment or blinding
Participants Participants with at least 2 focal or generalised tonic-clonic seizures per month
Unclear if participants were newly diagnosed
Number randomised: PHT = 45; SV = 49
27 participants (29%) focal epilepsy, 70 (74%) men
Age range: PHT: 12-42 years; SV: 8-52 years
Participants were evaluated after 4, 12 and 24 weeks of treatment
No information on range of follow-up
Interventions Monotherapy with PHT or SV
Average daily dose achieved: PHT: 5.6 mg/kg/day, SV: 18.8 mg/kg/day
Outcomes Reduction in frequency of seizures:
excellent (100% reduction)
good (75% - 99% reduction)
fair (50% - 74% reduction)
poor (< 50% reduction)
Adverse effects
Seizure control
Notes Outcomes chosen for this review were not reported. IPD not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants “randomly allocated irrespec-
tive of seizure type,” no further informa-
tion provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
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Rastogi 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Frequency of seizures reported for all ran-
domised participants, no information pro-
vided on treatment withdrawal rates/attri-
tion rates etc
Selective reporting (reporting bias) Low risk Frequency of seizures during treatmentwell
reported, most common adverse events re-
ported
No protocol available to compare with a
priori analysis plan, outcomes for this re-
view not reported
Other bias Low risk No other bias detected
Shakir 1981
Methods Parallel study design, outpatient setting
Study conducted in two centres (Glasgow, Scotland and Wellington, New Zealand)
Participants allocated using telephone randomisationwithin the two centres (information
provided by trial author)
No information provided on method of allocation concealment or blinding
Participants 21 (64%) participants previously untreated, 12 (36%) participants continued to have
seizures on previous drug therapies
Original treatments gradually withdrawn before PHT or SV treatment introduced
Number randomised: PHT = 15; SV = 18
19 participants (58%) with focal epilepsy, 12 (36%) men
Mean age (range): 23 (7-55 years). Mean follow-up (range): 30 (9-48 months)
Interventions Monotherapy with PHT or SV
Starting doses: PHT: < 12 years 150 mg/day, older participants: 300 mg/day
SV: < 12 years 300-400 mg/day, older participants: 800-1200 mg/day. Doses achieved
not stated
Outcomes Seizures during treatment
Adverse events
Notes Outcomes chosen for this review were not reported
IPD not available but could be constructed from the publication for the outcome ’time
to treatment failure’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants “randomly divided”, us-
ing telephone randomisation (information
provided by trial author)
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Shakir 1981 (Continued)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results reported for all randomised partic-
ipants, time on treatment reported for all
randomised participants. No losses to fol-
low-up reported
Selective reporting (reporting bias) Low risk Noprotocol available, outcomes chosen for
this review not reported. Seizure outcomes
and adverse events well reported
Other bias Low risk No other bias detected
Thilothammal 1996
Methods Parallel study design, outpatient setting
Study conducted in Madras (Chennai), India
Random list generated using computer-generated random numbers
Method of concealment not mentioned
Double-blind achieved by providing additional placebo tablets
Participants Childrenwithmore than 1 previously untreated generalised tonic-clonic (afebrile) seizure
Number randomised: PHT = 52; SV = 48
0% focal epilepsy. 52 (52%) men. Age range: 4-12 years
Range of follow-up (months): 22-36
Interventions Monotherapy with PHT or SV
Starting doses: PHT: 5-8 mg/kg/day, SV: 15-50 mg/kg/day
Dose achieved not stated
Outcomes Proportion with recurrence of seizures
Adverse events
Notes Outcomes chosen for this review were not reported. IPD not available
Risk of bias
Bias Authors’ judgement Support for judgement
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Thilothammal 1996 (Continued)
Random sequence generation (selection
bias)
Low risk Participants randomised via a computer-
generated list of random numbers
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blinded using additional placebo
tablets; unclear who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blinded using additional placebo
tablets; unclear who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed
Selective reporting (reporting bias) Low risk Noprotocol available; outcomes chosen for
this review not reported
Other bias Low risk No other bias detected
Turnbull 1985
Methods Parallel study design, outpatient setting
Study conducted in the UK
Participants allocated to treatment stratified by age group, gender and seizure type
No information provided on method of generation of random list, allocation conceal-
ment or blinding
Participants Participants with 2 or more focal or generalised tonic-clonic seizure in the past 3 years
Participants were previously untreated but started on antiepileptic drug treatment within
3 months of their most recent seizure
Number randomised: PHT = 70; SV = 70
63 participants (45%) with focal onset seizures, 73 (52%) men
Mean age (range): 35 (14-70 years). Range of follow-up: 24-48 months
Interventions Monotherapy with PHT or SV
Starting doses: PHT 300 mg/day, SV 600 mg/day. Dose achieved not stated
Outcomes Time to 2-year remission
Time to first seizure
Adverse events
Notes IPD provided for all outcomes included in this review
Risk of bias
Bias Authors’ judgement Support for judgement
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Turnbull 1985 (Continued)
Random sequence generation (selection
bias)
Unclear risk Participants randomised with stratification
for age group, gender and seizure type.
Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, ITT approach,
all randomised participants analysed from
IPD provided (see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk No other bias detected
1 Abbreviations:
IPD: individual participant data; ITT: intention-to-treat; PHT: phenytoin; SV: sodium valproate.
2 For studies which provided IPD, attrition and reporting bias are reduced as attrition rates and unpublished outcome data are requested
(Craig 1994; De Silva 1996; Heller 1995; Ramsay 1992; Turnbull 1985).
3 See Figure 2 and Figure 3 for ’Risk of bias’ summary and graph.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berg 1993 Reports the same trial as Forsythe 1991, but more relevant information given in the Forsythe publication
Callaghan 1981 Abstract only. Preliminary results of the trial reported in Callaghan 1985
Callaghan 1983 Abstract only. Preliminary results of the trial reported in Callaghan 1985
Callaghan 1984 Preliminary results of the trial reported in Callaghan 1985
Craig 1993 Abstract only. Preliminary results of the trial reported in Craig 1994
Czapinski 1997b Reports the same abstract as Czapinski 1997a
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(Continued)
Czapinski 1997c Reports the same abstract as Czapinski 1997a
Goggin 1984 Abstract only. Preliminary results of the trial reported in Callaghan 1985
Goggin 1986 Reports the same trial as Callaghan 1985, but more relevant information given in the Callaghan publication
Jannuzzi 2000 No randomised comparison of valproate and phenytoin (participants randomised to a dose adjustment method
rather than to a treatment)
Kaminow 2003 No randomised comparison of valproate and phenytoin (study of lamotrigine versus ’standard’ antiepileptic drug
treatment)
Sabers 1995 Not fully randomised: “The treatment was chosen at random unless the individual diagnoses required a specific
drug”
Schmidt 2007 No randomised comparison of valproate and phenytoin (post hoc analysis of 5 studies of oxcarbazepine versus
another antiepileptic drug)
Shakir 1980 Reports the same trial as Shakir 1981. There are some differences between the results in the 2 publications. The
reason for this could not be established
Tallis 1994a Abstract only. Reports the same trial as Craig 1994
Tallis 1994b Abstract only. Reports the same trial as Craig 1994
Turnbull 1982 Preliminary results of the trial reported in Turnbull 1985
Wilder 1983 Preliminary results of the trial reported in Turnbull 1985
Zeng 2010 Not randomised
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D A T A A N D A N A L Y S E S
Comparison 1. Sodium valproate versus phenytoin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to treatment failure (any
reason related to the treatment)
6 569 Hazard Ratio (Fixed, 95% CI) 0.94 [0.67, 1.32]
2 Time to treatment failure due to
adverse events
4 495 Hazard Ratio (Fixed, 95% CI) 0.68 [0.40, 1.17]
3 Time to treatment failure due to
lack of efficacy
6 569 Hazard Ratio (Fixed, 95% CI) 1.23 [0.77, 1.97]
4 Time to treatment failure (any
reason related to the treatment)
- by epilepsy type
5 528 Hazard Ratio (Fixed, 95% CI) 0.88 [0.61, 1.27]
4.1 Focal onset seizures 4 187 Hazard Ratio (Fixed, 95% CI) 0.83 [0.50, 1.38]
4.2 Generalised onset seizures
(tonic-clonic only)
5 341 Hazard Ratio (Fixed, 95% CI) 0.94 [0.55, 1.61]
5 Time to treatment failure due
to adverse events - by epilepsy
type
4 418 Hazard Ratio (Fixed, 95% CI) 0.77 [0.44, 1.37]
5.1 Focal onset seizures 3 168 Hazard Ratio (Fixed, 95% CI) 0.75 [0.35, 1.60]
5.2 Generalised onset seizures
(tonic-clonic only)
3 250 Hazard Ratio (Fixed, 95% CI) 0.81 [0.34, 1.90]
6 Time to treatment failure due to
lack of efficacy - by epilepsy
type
5 451 Hazard Ratio (Fixed, 95% CI) 1.16 [0.71, 1.89]
6.1 Focal onset seizures 4 187 Hazard Ratio (Fixed, 95% CI) 1.01 [0.55, 1.85]
6.2 Generalised onset seizures
(tonic-clonic only)
4 264 Hazard Ratio (Fixed, 95% CI) 1.51 [0.66, 3.45]
7 Time to first seizure 5 639 Hazard Ratio (Fixed, 95% CI) 1.04 [0.85, 1.28]
8 Time to first seizure - by epilepsy
type
5 639 Hazard Ratio (Fixed, 95% CI) 1.08 [0.88, 1.33]
8.1 Focal onset seizures 4 244 Hazard Ratio (Fixed, 95% CI) 1.20 [0.90, 1.60]
8.2 Generalised onset seizures
(tonic-clonic only)
5 395 Hazard Ratio (Fixed, 95% CI) 0.97 [0.72, 1.30]
9 Time to first seizure - epilepsy
type reclassified to focal for
generalised and age of onset >
30 years
5 639 Hazard Ratio (Fixed, 95% CI) 1.05 [0.86, 1.29]
9.1 Focal onset seizures 5 416 Hazard Ratio (Fixed, 95% CI) 1.23 [0.96, 1.57]
9.2 Generalised onset seizures
(tonic-clonic only)
4 223 Hazard Ratio (Fixed, 95% CI) 0.72 [0.50, 1.05]
10 Time to first seizure - epilepsy
type reclassified to uncertain
for generalised and age of onset
> 30 years
5 649 Hazard Ratio (Fixed, 95% CI) 1.06 [0.86, 1.30]
10.1 Focal onset seizures 4 255 Hazard Ratio (Fixed, 95% CI) 1.20 [0.90, 1.60]
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10.2 Generalised onset
seizures (tonic-clonic only)
4 223 Hazard Ratio (Fixed, 95% CI) 0.72 [0.50, 1.05]
10.3 Uncertain seizure type 4 171 Hazard Ratio (Fixed, 95% CI) 1.35 [0.85, 2.14]
11 Time to achieve 12-month
remission
4 514 Hazard Ratio (Fixed, 95% CI) 1.03 [0.82, 1.29]
12 Time to achieve 12-month
remission - by epilepsy type
4 514 Hazard Ratio (Fixed, 95% CI) 1.02 [0.81, 1.28]
12.1 Focal onset seizures 4 244 Hazard Ratio (Fixed, 95% CI) 1.11 [0.78, 1.60]
12.2 Generalised onset
seizures (tonic-clonic only)
4 270 Hazard Ratio (Fixed, 95% CI) 0.96 [0.71, 1.29]
13 Time to achieve six-month
remission
5 639 Hazard Ratio (Fixed, 95% CI) 1.08 [0.89, 1.30]
14 Time to achieve six-month
remission - by epilepsy type
5 639 Hazard Ratio (Fixed, 95% CI) 1.05 [0.86, 1.27]
14.1 Focal onset seizures 4 244 Hazard Ratio (Fixed, 95% CI) 1.00 [0.73, 1.35]
14.2 Generalised onset
seizures (tonic-clonic only)
5 395 Hazard Ratio (Fixed, 95% CI) 1.08 [0.84, 1.38]
Analysis 1.1. Comparison 1 Sodium valproate versus phenytoin, Outcome 1 Time to treatment failure (any
reason related to the treatment).
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 1 Time to treatment failure (any reason related to the treatment)
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
De Silva 1996 47 53 0.1302326 (0.3455843) 25.3 % 1.14 [ 0.58, 2.24 ]
Forsythe 1991 21 20 0.2493335 (0.5568347) 9.8 % 1.28 [ 0.43, 3.82 ]
Heller 1995 58 61 0.4868347 (0.3732047) 21.7 % 1.63 [ 0.78, 3.38 ]
Ramsay 1992 86 50 -0.4808784 (0.4175045) 17.4 % 0.62 [ 0.27, 1.40 ]
Shakir 1981 18 15 -0.5778984 (0.7640276) 5.2 % 0.56 [ 0.13, 2.51 ]
Turnbull 1985 70 70 -0.5504638 (0.3829445) 20.6 % 0.58 [ 0.27, 1.22 ]
Total (95% CI) 300 269 100.0 % 0.94 [ 0.67, 1.32 ]
Heterogeneity: Chi2 = 5.87, df = 5 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SV Favours PHT
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Analysis 1.2. Comparison 1 Sodium valproate versus phenytoin, Outcome 2 Time to treatment failure due
to adverse events.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 2 Time to treatment failure due to adverse events
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
De Silva 1996 47 53 0.0227243 (0.5569762) 24.8 % 1.02 [ 0.34, 3.05 ]
Heller 1995 58 61 1.164229 (0.6670092) 17.3 % 3.20 [ 0.87, 11.84 ]
Ramsay 1992 86 50 -1.251659 (0.6124484) 20.5 % 0.29 [ 0.09, 0.95 ]
Turnbull 1985 70 70 -0.8958756 (0.4532751) 37.4 % 0.41 [ 0.17, 0.99 ]
Total (95% CI) 261 234 100.0 % 0.68 [ 0.40, 1.17 ]
Heterogeneity: Chi2 = 9.20, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SV Favours PHT
63Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Sodium valproate versus phenytoin, Outcome 3 Time to treatment failure due
to lack of efficacy.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 3 Time to treatment failure due to lack of efficacy
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
De Silva 1996 47 53 0.1323596 (0.3682655) 42.3 % 1.14 [ 0.55, 2.35 ]
Forsythe 1991 21 20 0.7612669 (1.226101) 3.8 % 2.14 [ 0.19, 23.67 ]
Heller 1995 58 61 0.4937075 (0.4088837) 34.3 % 1.64 [ 0.74, 3.65 ]
Ramsay 1992 86 50 -0.5559053 (1.414291) 2.9 % 0.57 [ 0.04, 9.17 ]
Shakir 1981 18 15 -0.5778984 (0.7640276) 9.8 % 0.56 [ 0.13, 2.51 ]
Turnbull 1985 70 70 0.4266949 (0.9149673) 6.9 % 1.53 [ 0.25, 9.21 ]
Total (95% CI) 300 269 100.0 % 1.23 [ 0.77, 1.97 ]
Heterogeneity: Chi2 = 2.14, df = 5 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SV Favours PHT
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Analysis 1.4. Comparison 1 Sodium valproate versus phenytoin, Outcome 4 Time to treatment failure (any
reason related to the treatment) - by epilepsy type.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 4 Time to treatment failure (any reason related to the treatment) - by epilepsy type
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
De Silva 1996 24 30 0.0503293 (0.450606) 17.3 % 1.05 [ 0.43, 2.54 ]
Heller 1995 24 27 -0.0368511 (0.5063818) 13.7 % 0.96 [ 0.36, 2.60 ]
Shakir 1981 10 9 -1.013038 (0.8672786) 4.7 % 0.36 [ 0.07, 1.99 ]
Turnbull 1985 32 31 -0.3019101 (0.4500872) 17.4 % 0.74 [ 0.31, 1.79 ]
Subtotal (95% CI) 90 97 53.0 % 0.83 [ 0.50, 1.38 ]
Heterogeneity: Chi2 = 1.34, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
2 Generalised onset seizures (tonic-clonic only)
De Silva 1996 23 23 0.5257109 (0.5757865) 10.6 % 1.69 [ 0.55, 5.23 ]
Heller 1995 34 34 1.341457 (0.6533459) 8.2 % 3.82 [ 1.06, 13.76 ]
Ramsay 1992 86 50 -0.4808784 (0.4175045) 20.2 % 0.62 [ 0.27, 1.40 ]
Shakir 1981 8 6 -1.153731 (1.18734) 2.5 % 0.32 [ 0.03, 3.23 ]
Turnbull 1985 38 39 -1.267952 (0.8018506) 5.5 % 0.28 [ 0.06, 1.35 ]
Subtotal (95% CI) 189 152 47.0 % 0.94 [ 0.55, 1.61 ]
Heterogeneity: Chi2 = 9.77, df = 4 (P = 0.04); I2 =59%
Test for overall effect: Z = 0.22 (P = 0.82)
Total (95% CI) 279 249 100.0 % 0.88 [ 0.61, 1.27 ]
Heterogeneity: Chi2 = 11.21, df = 8 (P = 0.19); I2 =29%
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 1.5. Comparison 1 Sodium valproate versus phenytoin, Outcome 5 Time to treatment failure due
to adverse events - by epilepsy type.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 5 Time to treatment failure due to adverse events - by epilepsy type
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
De Silva 1996 24 30 -0.4952395 (0.8665633) 11.2 % 0.61 [ 0.11, 3.33 ]
Heller 1995 24 27 0.5590296 (0.913253) 10.1 % 1.75 [ 0.29, 10.47 ]
Turnbull 1985 32 31 -0.4684627 (0.4932097) 34.6 % 0.63 [ 0.24, 1.65 ]
Subtotal (95% CI) 80 88 56.0 % 0.75 [ 0.35, 1.60 ]
Heterogeneity: Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Generalised onset seizures (tonic-clonic only)
De Silva 1996 23 23 0.4045718 (0.7654851) 14.4 % 1.50 [ 0.33, 6.72 ]
Heller 1995 34 34 1.781216 (1.081279) 7.2 % 5.94 [ 0.71, 49.43 ]
Ramsay 1992 86 50 -1.251659 (0.6124484) 22.5 % 0.29 [ 0.09, 0.95 ]
Subtotal (95% CI) 143 107 44.0 % 0.81 [ 0.34, 1.90 ]
Heterogeneity: Chi2 = 6.93, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 223 195 100.0 % 0.77 [ 0.44, 1.37 ]
Heterogeneity: Chi2 = 8.00, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 1.6. Comparison 1 Sodium valproate versus phenytoin, Outcome 6 Time to treatment failure due
to lack of efficacy - by epilepsy type.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 6 Time to treatment failure due to lack of efficacy - by epilepsy type
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
De Silva 1996 24 30 0.1478334 (0.4872691) 26.2 % 1.16 [ 0.45, 3.01 ]
Heller 1995 24 27 0.0887007 (0.5202708) 23.0 % 1.09 [ 0.39, 3.03 ]
Shakir 1981 10 9 -1.013038 (0.8672786) 8.3 % 0.36 [ 0.07, 1.99 ]
Turnbull 1985 32 31 0.4027622 (0.9157529) 7.4 % 1.50 [ 0.25, 9.00 ]
Subtotal (95% CI) 90 97 64.9 % 1.01 [ 0.55, 1.85 ]
Heterogeneity: Chi2 = 1.68, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
2 Generalised onset seizures (tonic-clonic only)
De Silva 1996 23 23 0.3976139 (0.5922896) 17.7 % 1.49 [ 0.47, 4.75 ]
Heller 1995 34 34 1.444474 (0.7933815) 9.9 % 4.24 [ 0.90, 20.07 ]
Ramsay 1992 86 50 -0.5559053 (1.414291) 3.1 % 0.57 [ 0.04, 9.17 ]
Shakir 1981 8 6 -1.153731 (1.18734) 4.4 % 0.32 [ 0.03, 3.23 ]
Subtotal (95% CI) 151 113 35.1 % 1.51 [ 0.66, 3.45 ]
Heterogeneity: Chi2 = 3.90, df = 3 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 241 210 100.0 % 1.16 [ 0.71, 1.89 ]
Heterogeneity: Chi2 = 6.18, df = 7 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
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Analysis 1.7. Comparison 1 Sodium valproate versus phenytoin, Outcome 7 Time to first seizure.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 7 Time to first seizure
Study or subgroup Sodium Valproate Phneytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Craig 1994 76 71 0.3181922 (0.2244793) 21.7 % 1.37 [ 0.89, 2.13 ]
De Silva 1996 49 54 0.1782427 (0.212387) 24.2 % 1.20 [ 0.79, 1.81 ]
Heller 1995 61 63 -0.1352178 (0.2101813) 24.7 % 0.87 [ 0.58, 1.32 ]
Ramsay 1992 77 48 -0.3404679 (0.3046172) 11.8 % 0.71 [ 0.39, 1.29 ]
Turnbull 1985 70 70 0.0107838 (0.2483094) 17.7 % 1.01 [ 0.62, 1.64 ]
Total (95% CI) 333 306 100.0 % 1.04 [ 0.85, 1.28 ]
Heterogeneity: Chi2 = 4.23, df = 4 (P = 0.38); I2 =5%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Sodium valproate versus phenytoin, Outcome 8 Time to first seizure - by
epilepsy type.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 8 Time to first seizure - by epilepsy type
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Craig 1994 35 39 0.3612121 (0.2863956) 13.5 % 1.44 [ 0.82, 2.52 ]
De Silva 1996 25 29 0.3475484 (0.2829562) 13.8 % 1.42 [ 0.81, 2.46 ]
Heller 1995 25 28 -0.0760854 (0.3141979) 11.2 % 0.93 [ 0.50, 1.72 ]
Turnbull 1985 32 31 0.0359664 (0.2991871) 12.3 % 1.04 [ 0.58, 1.86 ]
Subtotal (95% CI) 117 127 50.8 % 1.20 [ 0.90, 1.60 ]
Heterogeneity: Chi2 = 1.65, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
2 Generalised onset seizures (tonic-clonic only)
Craig 1994 41 32 0.5379524 (0.3726711) 8.0 % 1.71 [ 0.82, 3.56 ]
De Silva 1996 24 25 0.0887026 (0.3248738) 10.5 % 1.09 [ 0.58, 2.07 ]
Heller 1995 36 35 -0.1302678 (0.2869063) 13.4 % 0.88 [ 0.50, 1.54 ]
Ramsay 1992 77 48 -0.3404679 (0.3046172) 11.9 % 0.71 [ 0.39, 1.29 ]
Turnbull 1985 38 39 -0.1998695 (0.4500084) 5.5 % 0.82 [ 0.34, 1.98 ]
Subtotal (95% CI) 216 179 49.2 % 0.97 [ 0.72, 1.30 ]
Heterogeneity: Chi2 = 3.76, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 333 306 100.0 % 1.08 [ 0.88, 1.33 ]
Heterogeneity: Chi2 = 6.46, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 1.06, df = 1 (P = 0.30), I2 =6%
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Analysis 1.9. Comparison 1 Sodium valproate versus phenytoin, Outcome 9 Time to first seizure - epilepsy
type reclassified to focal for generalised and age of onset > 30 years.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 9 Time to first seizure - epilepsy type reclassified to focal for generalised and age of onset > 30 years
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Craig 1994 76 71 0.3181922 (0.2244793) 21.5 % 1.37 [ 0.89, 2.13 ]
De Silva 1996 25 30 0.3475484 (0.2829562) 13.5 % 1.42 [ 0.81, 2.46 ]
Heller 1995 42 48 0.0247767 (0.2440295) 18.2 % 1.03 [ 0.64, 1.65 ]
Ramsay 1992 16 10 -0.1386625 (0.5882093) 3.1 % 0.87 [ 0.27, 2.76 ]
Turnbull 1985 48 50 0.214126 (0.2757868) 14.2 % 1.24 [ 0.72, 2.13 ]
Subtotal (95% CI) 207 209 70.5 % 1.23 [ 0.96, 1.57 ]
Heterogeneity: Chi2 = 1.40, df = 4 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
2 Generalised onset seizures (tonic-clonic only)
De Silva 1996 24 24 -0.0550076 (0.2992163) 12.1 % 0.95 [ 0.53, 1.70 ]
Heller 1995 19 15 -0.6157811 (0.4299204) 5.9 % 0.54 [ 0.23, 1.25 ]
Ramsay 1992 61 38 -0.3922214 (0.3570182) 8.5 % 0.68 [ 0.34, 1.36 ]
Turnbull 1985 22 20 -0.6502508 (0.5882777) 3.1 % 0.52 [ 0.16, 1.65 ]
Subtotal (95% CI) 126 97 29.5 % 0.72 [ 0.50, 1.05 ]
Heterogeneity: Chi2 = 1.61, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
Total (95% CI) 333 306 100.0 % 1.05 [ 0.86, 1.29 ]
Heterogeneity: Chi2 = 8.47, df = 8 (P = 0.39); I2 =6%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 5.46, df = 1 (P = 0.02), I2 =82%
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Analysis 1.10. Comparison 1 Sodium valproate versus phenytoin, Outcome 10 Time to first seizure -
epilepsy type reclassified to uncertain for generalised and age of onset > 30 years.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 10 Time to first seizure - epilepsy type reclassified to uncertain for generalised and age of onset > 30 years
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Craig 1994 35 39 0.3612121 (0.2863956) 13.3 % 1.44 [ 0.82, 2.52 ]
De Silva 1996 35 30 0.3475484 (0.2829562) 13.7 % 1.42 [ 0.81, 2.46 ]
Heller 1995 25 28 -0.0760854 (0.3141979) 11.1 % 0.93 [ 0.50, 1.72 ]
Turnbull 1985 32 31 0.0359664 (0.2991871) 12.2 % 1.04 [ 0.58, 1.86 ]
Subtotal (95% CI) 127 128 50.3 % 1.20 [ 0.90, 1.60 ]
Heterogeneity: Chi2 = 1.65, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
2 Generalised onset seizures (tonic-clonic only)
De Silva 1996 24 24 -0.0550076 (0.2992163) 12.2 % 0.95 [ 0.53, 1.70 ]
Heller 1995 19 15 -0.6157811 (0.4299204) 5.9 % 0.54 [ 0.23, 1.25 ]
Ramsay 1992 61 38 -0.3922214 (0.3570182) 8.6 % 0.68 [ 0.34, 1.36 ]
Turnbull 1985 22 20 -0.6502508 (0.5882777) 3.2 % 0.52 [ 0.16, 1.65 ]
Subtotal (95% CI) 126 97 29.9 % 0.72 [ 0.50, 1.05 ]
Heterogeneity: Chi2 = 1.61, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
3 Uncertain seizure type
Craig 1994 41 32 0.5379524 (0.3726711) 7.9 % 1.71 [ 0.82, 3.56 ]
Heller 1995 17 20 0.2102119 (0.4054857) 6.7 % 1.23 [ 0.56, 2.73 ]
Ramsay 1992 16 10 -0.1386625 (0.5882093) 3.2 % 0.87 [ 0.27, 2.76 ]
Turnbull 1985 16 19 0.3485742 (0.7101326) 2.2 % 1.42 [ 0.35, 5.70 ]
Subtotal (95% CI) 90 81 19.9 % 1.35 [ 0.85, 2.14 ]
Heterogeneity: Chi2 = 1.02, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 343 306 100.0 % 1.06 [ 0.86, 1.30 ]
Heterogeneity: Chi2 = 10.07, df = 11 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 5.79, df = 2 (P = 0.06), I2 =65%
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Analysis 1.11. Comparison 1 Sodium valproate versus phenytoin, Outcome 11 Time to achieve 12-month
remission.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 11 Time to achieve 12-month remission
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Craig 1994 76 71 0.0283633 (0.3661886) 10.0 % 1.03 [ 0.50, 2.11 ]
De Silva 1996 49 54 -0.0217975 (0.210136) 30.4 % 0.98 [ 0.65, 1.48 ]
Heller 1995 61 63 0.0061241 (0.2139549) 29.3 % 1.01 [ 0.66, 1.53 ]
Turnbull 1985 70 70 0.1008905 (0.2102497) 30.3 % 1.11 [ 0.73, 1.67 ]
Total (95% CI) 256 258 100.0 % 1.03 [ 0.82, 1.29 ]
Heterogeneity: Chi2 = 0.19, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Sodium valproate versus phenytoin, Outcome 12 Time to achieve 12-month
remission - by epilepsy type.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 12 Time to achieve 12-month remission - by epilepsy type
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Craig 1994 35 39 0.1555318 (0.7313448) 2.6 % 1.17 [ 0.28, 4.90 ]
De Silva 1996 25 29 0.0760277 (0.302138) 15.0 % 1.08 [ 0.60, 1.95 ]
Heller 1995 25 28 0.0674705 (0.3313083) 12.5 % 1.07 [ 0.56, 2.05 ]
Turnbull 1985 32 31 0.188102 (0.3597993) 10.6 % 1.21 [ 0.60, 2.44 ]
Subtotal (95% CI) 117 127 40.5 % 1.11 [ 0.78, 1.60 ]
Heterogeneity: Chi2 = 0.08, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
2 Generalised onset seizures (tonic-clonic only)
Craig 1994 41 32 -0.4546067 (0.4280954) 7.5 % 0.63 [ 0.27, 1.47 ]
De Silva 1996 24 25 -0.0550076 (0.2992163) 15.3 % 0.95 [ 0.53, 1.70 ]
Heller 1995 36 35 -0.0731418 (0.2817296) 17.2 % 0.93 [ 0.54, 1.61 ]
Turnbull 1985 38 39 0.1563242 (0.2645745) 19.5 % 1.17 [ 0.70, 1.96 ]
Subtotal (95% CI) 139 131 59.5 % 0.96 [ 0.71, 1.29 ]
Heterogeneity: Chi2 = 1.50, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 256 258 100.0 % 1.02 [ 0.81, 1.28 ]
Heterogeneity: Chi2 = 1.97, df = 7 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 0.39, df = 1 (P = 0.53), I2 =0.0%
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Analysis 1.13. Comparison 1 Sodium valproate versus phenytoin, Outcome 13 Time to achieve six-month
remission.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 13 Time to achieve six-month remission
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Craig 1994 76 71 -0.0420148 (0.2134655) 20.7 % 0.96 [ 0.63, 1.46 ]
De Silva 1996 49 54 0.0307476 (0.2097395) 21.5 % 1.03 [ 0.68, 1.56 ]
Heller 1995 61 63 0.0515765 (0.1992782) 23.8 % 1.05 [ 0.71, 1.56 ]
Ramsay 1992 77 48 0.4240952 (0.3099105) 9.8 % 1.53 [ 0.83, 2.81 ]
Turnbull 1985 70 70 0.0947976 (0.1972994) 24.2 % 1.10 [ 0.75, 1.62 ]
Total (95% CI) 333 306 100.0 % 1.08 [ 0.89, 1.30 ]
Heterogeneity: Chi2 = 1.64, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Sodium valproate versus phenytoin, Outcome 14 Time to achieve six-month
remission - by epilepsy type.
Review: Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Sodium valproate versus phenytoin
Outcome: 14 Time to achieve six-month remission - by epilepsy type
Study or subgroup Sodium Valproate Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Craig 1994 35 39 -0.0144671 (0.3170963) 9.6 % 0.99 [ 0.53, 1.83 ]
De Silva 1996 25 29 0.04262 (0.3029103) 10.5 % 1.04 [ 0.58, 1.89 ]
Heller 1995 25 28 0.0520522 (0.3141471) 9.8 % 1.05 [ 0.57, 1.95 ]
Turnbull 1985 32 31 -0.1020412 (0.3203492) 9.4 % 0.90 [ 0.48, 1.69 ]
Subtotal (95% CI) 117 127 39.3 % 1.00 [ 0.73, 1.35 ]
Heterogeneity: Chi2 = 0.15, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 Generalised onset seizures (tonic-clonic only)
Craig 1994 41 32 -0.3330577 (0.295571) 11.0 % 0.72 [ 0.40, 1.28 ]
De Silva 1996 24 25 0.0554472 (0.2968083) 11.0 % 1.06 [ 0.59, 1.89 ]
Heller 1995 36 35 0.0004267 (0.2600405) 14.3 % 1.00 [ 0.60, 1.67 ]
Ramsay 1992 77 48 0.4240952 (0.3099105) 10.0 % 1.53 [ 0.83, 2.81 ]
Turnbull 1985 38 39 0.2416645 (0.2590662) 14.4 % 1.27 [ 0.77, 2.12 ]
Subtotal (95% CI) 216 179 60.7 % 1.08 [ 0.84, 1.38 ]
Heterogeneity: Chi2 = 3.68, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 333 306 100.0 % 1.05 [ 0.86, 1.27 ]
Heterogeneity: Chi2 = 3.99, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Demographic characteristics of trial participants (trials providing individual participant data (IPD))
Focal seizures: n
(%)
Male gender: n
(%)
Age at entry
(years):
Mean (SD), range
Aged > 30 years
and generalised
seizures: n (%)
Epilepsy duration
(years): mean
(SD), range
Number of
seizures in prior
6months:median
(range)
SV
PHT Miss-
ing
SV
PHT Miss-
ing
SV
PHT Miss-
ing
SV
PHT Miss-
ing
SV
PHT Miss-
ing
SV
PHT Miss-
ing
Craig
1994
37
(44%)
43
(53%)
0 38
(46%)
33
(41%)
3 77.
6 (7.
2)
, 61
to
95
78.
7 (7.
0)
, 64
to
95
3 46 38 0 NA NA 166 2
(0 to
60)
3
(1 to
99)
3
De
Silva
1996
25
(51%)
30
(56%)
0 18
(37%)
34
(63%)
0 11.
3 (3.
3), 2
to
15
9.
5 (3.
4), 3
to
15
0 0 0 0 1.
2 (1.
5), 0
to 4.
9
1.
0 (2.
1), 0
to
13.7
0 3
(1 to
900)
3
(1 to
404)
0
Heller
1995
25
(41%)
28
(44%)
0 28
(46%)
34
(54%)
0 32.0
(15.
6)
, 14
to
67
33.5
(14.
3)
, 14
to
72
2 17 20 0 2.
6 (3.
9), 0
to
17.9
3.
8 (5.
4), 0
to
24.3
2 2
(1 to
181)
2
(1 to
575)
2
Ram-
say
1992
0
(0%)
0
(0%)
0 48
(56%)
25
(50%)
0 21.1
(14.
4), 3
to
64
20.6
(14.
0), 4
to
63
0 16 10 0 0.
1 (0.
3), 0
to 1.
9
0.
2 (0.
5), 0
to 3.
0
15 NA NA 136
Turn-
bull
1985
32
(46%)
31
(44%)
0 34
(49%)
39
(56%)
0 35.1
(16.
5)
, 14
to
69
35.3
(15.
9)
, 16
to
70
0 16 19 0 2.
2 (2.
9)
, 0.
1 to
11.0
2.
1 (4.
2)
, 0.
1 to
30.0
0 2
(0 to
60)
2
(1 to
60)
0
SV= sodium valproate; PHT= Phenytoin; n = number of participants; NA = not available; SD = standard deviation.
Proportions (%) are calculated based on non-missing data.
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Table 2. Baseline neurologic characteristics of participants (trials providing individual participant data (IPD))
EEG normal: n (%) CT scan normal: n (%) Neurological exam normal: n (%)
SV PHT Missing SV PHT Missing SV PHT Missing
Craig 1994 20 (30%) 8 (16%) 64 NA NA 166 NA NA 166
De Silva
1996
NA NA 103 NA NA 103 43 (88%) 48 (89%) 0
Heller
1995
NA NA 124 NA NA 124 56 (95%) 54 (86%) 2
Ramsay
1992
NA NA 136 NA NA 136 NA NA 136
Turnbull
1985
30 (46%) 38 (54%) 0 6 (50%) 11 (73%) 43 NA NA 70
EEG = electroencephalographic; SV= sodium valproate; PHT= Phenytoin; n = number of participants; NA = not available.
Proportions (%) are calculated based on non-missing data.
Table 3. Outcomes considered and summary of results for trials with no individual participant data (IPD)
Trial Outcomes reported Summary of results
Callaghan 1985 • Seizure control
◦ excellent (seizure-free)
◦ good (> 50% reduction)
◦ poor (< 50% reduction)
• Adverse events
• PHT (n = 58); SV (n = 64)
◦ 39 (67%); 34 (53%)
◦ 7 (12%); 16 (25%)
◦ 12 (21%); 14 (22%)
• 2.6 (10%); 7 (11%)
Czapinski 1997a • Proportion achieving 24-month remission at 3
years (PHT: 59%; SV: 64%)
• Proportion excluded after randomisation due to
adverse events or no efficacy (PHT: 23%; SV: 23%)
• Proportion achieving 24-month remission at 3
years (PHT: 59%; SV: 64%)
• Proportion excluded after randomisation due to
adverse events or no efficacy (PHT: 23%; SV: 23%)
Forsythe 1991 • Cognitive assessments
• Withdrawals from randomised drug
• Significant difference favouring SV test of speed
of information processing (P < 0.01)
No significant differences between treatment groups
for any other cognitive tests
• PHT: 6/20 (30%); SV: 7/21 (33%)
Rastogi 1991 • Reduction in frequency of seizures at 24 weeks
◦ excellent (100% reduction)
◦ good (75% - 99% reduction)
◦ fair (50% - 74% reduction)
◦ poor (< 50% reduction)
• PHT (n = 45); SV (n = 49)
◦ 23 (51%); 24 (49%)
◦ 13 (24%); 17 (35%)
◦ 8 (18%); 5(10%)
◦ 1 (2%); 3 (6%)
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Table 3. Outcomes considered and summary of results for trials with no individual participant data (IPD) (Continued)
• Adverse events • All reported adverse events were minor
◦ PHT: gum hyperplasia (18%), nystagmus
(13%), gastrointestinal symptoms (4%), drowsiness
(4%), ataxia (2%)
◦ SV: gastrointestinal symptoms (12%),
drowsiness (6%), weight gain (2%)
Shakir 1981 • Seizures during treatment
• Adverse events
• PHT: 5 (33%); SV: 7 (39%)
• PHT: 1 case of ataxia, 5 cases of acne
• SV: 2 cases of gastrointestinal symptoms, 2
cases of hair loss, 4 cases of weight gain
Thilothammal 1996 • Recurrence of seizures
• Adverse events
• PHT: 14/52 (27%)/SV: 10/48 (21%)
• PHT: 33/52 (63%)/SV: 15/48 (31%)
n = number of participants; PHT: phenytoin; SV: sodium valproate.
Table 4. Number of individuals contributing to each analysis
Trial Number
randomised
Time to treatment
failure (for any rea-
son related to treat-
ment)
Time to achieve 12-
month remission
Time to achieve 6-
month remission
Time to first seizure
PHT SV Total PHT SV Total PHT SV Total PHT SV Total PHT SV Total
Craig
1994
a
81 85 166 0 0 0 71 76 147 71 76 147 71 76 147
De
Silva
1996
54 49 103 53 47 100 54 49 103 54 49 103 54 49 103
Forsythe
1991
b
20 21 41 20 21 41 0 0 0 0 0 0 0 0 0
Heller
1995
63 61 124 61 58 119 63 61 124 63 61 124 63 61 124
Ram-
say
1992
c
50 86 136 50 86 136 0 0 0 48 77 125 48 77 125
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Table 4. Number of individuals contributing to each analysis (Continued)
Turn-
bull
1985
70 70 140 70 70 140 70 70 140 70 70 140 70 70 140
Shakir
1981
b
15 18 33 15 18 33 0 0 0 0 0 0 0 0 0
Total 353 390 743 269 300 569 258 256 514 306 333 639 306 333 639
aTreatment failure information not provided for Craig 1994, so cannot contribute to ’time to treatment failure’.
bData extracted from Forsythe 1991 and Shakir 1981 publications to calculate time to treatment failure. Insufficient published data to
calculate other outcomes.
cFollow-up for Ramsay 1992 is less than 12 months so cannot contribute to ’time to achieve 12-month remission’.
PHT: phenytoin; SV: sodium valproate.
Table 5. Reasons for premature discontinuation (treatment failure)
Rea-
son
for
early
ter-
mi-
na-
tion
(and
clas-
sifi-
ca-
tion
in
time-
to-
event
anal-
ysis)
De Silva 1996
b
Heller 1995
b,c
Ramsay 1992 Turnbull
1985
Forsythe
1991
Shakir 1981d Totala
SV PHT SV PHT SV PHT SV PHT SV PHT SV PHT SV PHT All
Ad-
verse
events
(event)
2 2 4 1 4 8 6 14 0 1 0 0 16 26 42
Lack
of ef-
ficacy
(event)
11 10 9 8 1 1 2 0 2 1 3 6 28 26 54
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Table 5. Reasons for premature discontinuation (treatment failure) (Continued)
Both
ad-
verse
events
and
lack
of ef-
ficacy
(event)
4 5 6 2 0 0 1 2 0 0 0 0 11 9 20
Non-
com-
pli-
ance/
pro-
tocol
viola-
tion
(event)
0 0 0 0 7 2 2 2 5 4 0 0 14 8 22
Ill-
ness
or
death
(not
treat-
ment-
re-
lated,
cen-
sored)
e
0 0 0 0 1 1 3 3 0 0 0 0 4 4 8
Par-
tici-
pant
went
into
re-
mis-
sion
(cen-
sored)
16 24 13 14 0 0 0 0 0 0 0 0 29 38 67
Lost
to fol-
low-
up
(cen-
0 0 0 0 10 3 7 7 0 0 0 0 17 10 27
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Table 5. Reasons for premature discontinuation (treatment failure) (Continued)
sored)
Other
(cen-
sored)
f
0 0 0 0 3 0 0 0 0 0 0 0 3 0 3
Com-
pleted
the
study
(cen-
sored)
14 12 26 38 60 35 49 42 14 14 15 9 178 150 328
Total 47 53 58 63 86 50 70 70 21 20 18 15 300 271 571
PHT: phenytoin; SV: sodium valproate
aIPD for ’time to treatment failure’ was not provided for Craig 1994.
bThree participants for Heller 1995 (all SV) and three for De Silva 1996 (one PHT and two SV) have missing reasons for treatment
failure.
cFour participants from Heller 1995 had missing treatment failure times and did not contribute to analysis but reasons for treatment
failure are given.
dNine participants in Shakir 1981 were listed as having started on a second drug due to ’failure to respond.’ This reason was classified
as treatment failure due to lack of efficacy.
eDeath due to reasons not related to the study drug.
fOther reasons from Ramsay 1992 - two participants withdrew due to pregnancy and one for personal reasons.
Table 6. Sensitivity analysis - epilepsy type misclassification
Outcome Original analysis Generalised onset and age at onset
> 30 years
classified as focal onset
Generalised onset and age at onset
> 30 years
classified as uncertain seizure type
Pooled HR
(95% CI)
fixed-effects
Test of
subgroup
differences
Pooled HR
(95% CI)
fixed-effects
Test of
subgroup
differences
Pooled HR
(95% CI)
fixed-effects
Test of
subgroup
differences
Time to treat-
ment failure
(for any reason
related to treat-
ment)a
F: 0.83 (0.50 to
1.38)
G: 0.94 (0.55 to
1.61)
O: 0.88 (0.61 to
1.27)
Chi² = 0.10, df =
1
(P = 0.75), I² =
0%
F: 0.95 (0.59 to
1.52)
G: 0.77 (0.42 to
1.41)
O: 0.88 (0.60 to
1.27)
Chi² = 0.29, df =
1
(P = 0.59), I² =
0%
F: 0.83 (0.50 to
1.38)
G: 0.77 (0.42 to
1.41)
U: 6.83 (0.82 to
57.16)
O: 0.86 (0.59 to
1.27)
Chi² = 3.80, df =
2
(P = 0.15), I² =
47.3%
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Table 6. Sensitivity analysis - epilepsy type misclassification (Continued)
Time to treat-
ment failure due
to adverse events
b
F: 0.75 (0.35 to
1.60)
G: 0.81 (0.34 to
1.90)
O: 0.77 (0.44 to
1.37)
Chi² = 0.02, df =
1
(P = 0.90), I² =
0%
F: 0.87 (0.42 to
1.80)
G: 0.64 (0.26 to
1.59)
O: 0.77 (0.44 to
1.36)
Chi² = 0.26, df =
1
(P = 0.61), I² =
0%
Not calculatedb Not calculatedb
Time to treat-
ment failure due
to lack of efficacy
b
F: 1.01 (0.55 to
1.85)
G: 1.51 (0.66 to
3.45)
O: 1.16 (0.71 to
1.89)
Chi² = 0.60, df =
1
(P = 0.44), I² =
0%
F: 1.00 (0.51 to
1.96)
G: 1.73 (0.56 to
5.35)
O: 1.16 (0.65 to
2.06)
Chi² = 0.66, df =
1
(P = 0.42), I² =
0%
Not calculatedb Not calculatedb
Time to first
seizurec
F: 1.20 (0.90 to
1.60)
G: 0.97 (0.72 to
1.30)
O: 1.08 (0.88 to
1.33)
Chi² = 1.06, df =
1
(P = 0.30), I² = 5.
6%
F: 1.23 (0.96 to
1.57)
G: 0.72 (0.50 to
1.05)
O: 1.05 (0.86 to
1.29)
Chi² = 5.46, df =
1
(P = 0.02), I² =
81.7%
F: 1.20 (0.90 to
1.60)
G: 0.72 (0.50 to
1.05)
U: 1.35 (0.85 to
2.14)
O: 1.06 (0.86 to
1.30)
Chi² = 5.79, df =
2
(P = 0.06), I² =
65.5%
Time to 12-
month remission
d
F: 1.11 (0.78 to
1.60)
G: 0.96 (0.71 to
1.29)
O: 1.02 (0.81 to
1.28)
Chi² = 0.39, df =
1
(P = 0.53), I² =
0%
F: 0.99 (0.75 to
1.32)
G: 1.07 (0.72 to
1.59)
O: 1.02 (0.81 to
1.28)
Chi² = 0.10, df =
1
(P = 0.75), I² =
0%
F: 1.11 (0.78 to
1.60)
G: 1.07 (0.72 to
1.59)
U: 0.74 (0.46 to
1.18)
O: 0.99 (0.79 to
1.25)
Chi² = 2.07, df =
2
(P = 0.36), I² = 3.
3%
Time to 6-
month remission
e
F: 1.00 (0.73 to
1.35)
G: 1.08 (0.84 to
1.38)
O: 1.05 (0.86 to
1.27)
Chi² = 0.16, df =
1
(P = 0.69), I² =
0%
F: 1.00 (0.79 to
1.26)
G: 1.14 (0.80 to
1.61)
O: 1.04 (0.85 to
1.26)
Chi² = 0.38, df =
1
(P = 0.54), I² =
0%
F: 1.00 (0.73 to
1.35)
G: 1.14 (0.80 to
1.61)
U: 0.90 (0.62 to
1.31)
O: 1.01 (0.83 to
1.23)
Chi² = 0.80, df =
2
(P = 0.67), I² =
0%
Chi²: Chi² statistic; df: degrees of freedom of Chi² distribution; F: focal epilepsy; G: generalised epilepsy; O: overall (all participants);
U: uncertain epilepsy; P: P value (< 0.05 are classified as statistically significant).
a100 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome ’time to treatment failure (for any reason related
to treatment)’; see Analysis 1.4 for original analysis.
b100 participants reclassified to focal epilepsy or uncertain epilepsy type for outcomes ’time to treatment failure due to adverse events’
and ’time to treatment failure due to lack of efficacy’; see Analysis 1.5 and Analysis 1.6 for original analyses. Forest plots not presented
for sensitivity analysis for generalised and age at onset > 30 years reclassified as focal epilepsy as results were numerically similar and
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conclusions are unchanged. Sensitivity analysis for generalised and age at onset > 30 years reclassified as uncertain epilepsy type not
performed due to small numbers of participants failing treatment for these reasons in the uncertain epilepsy type groups in each trial.
c171 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome ’time to first seizure’; see Analysis 1.8 for original
analysis and see Analysis 1.10 and Analysis 1.9 for forest plots of ’time to first seizure’ sensitivity analyses for generalised and age at
onset > 30 years reclassified as focal epilepsy and uncertain epilepsy type, respectively.
d145 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome ’time to achieve 12-month remission’, see Analysis
1.12 for original analysis. As results were numerically similar and conclusions are unchanged, forest plots are not presented.
e171 participants reclassified to focal epilepsy or uncertain epilepsy type for outcome ’time to achieve 6-month remission’, see Analysis
1.14 for original analysis. As results were numerically similar and conclusions are unchanged, forest plots are not presented.
Table 7. Adverse event data (narrative report)
Trial Adverse event dataa Summary of reported results
Phenytoin (PHT) SV (sodium valproate)
Callaghan 1985 All adverse events developed (by
drug) and adverse events leading to
discontinuation of treatment
PHT (n = 58): gum hypertrophy (n
= 2), rash (n = 2), ataxia (n = 2)
SV (n = 64): weight gain (n = 4: all
discontinued treatment), drowsi-
ness (n = 2), aggressive behaviour
(n = 1: discontinued treatment)
Craig 1994 Adverse event frequency (sponta-
neous reports)b
Discontinuations due to adverse
eventsc
PHT (n = 25): unsteadiness (n = 9)
, sleepiness (n = 7), drowsiness (n =
2), impaired concentration (n = 2),
confusion (n = 1), constipation (n
= 1), diarrhoea (n = 1), dysarthria
(n = 1), lethargy (n = 1), nystagmus
(n = 1), rash (n = 1), tired legs (n =
1)
PHT discontinuations (n = 6): rash
(n =1), diarrhoea (n = 1), confusion
(n = 1), unsteadiness (n = 1), con-
stipation (n = 1), sleepiness (n = 1)
SV (n = 17): unsteadiness (n = 2)
, sleepiness (n = 3), tremor (n = 5)
, oedema (n = 3), alopecia (n = 2),
depression (n = 2), weight gain (n
= 2)
SVdiscontinuations (n =2): weight
gain and depression (n = 1), un-
steadiness (n =1)
Czapinski 1997a “Exclusions” due to adverse events
or no efficacyd
Proportion “excluded”: PHT: 33.
3%
Proportion “excluded”: SV: 23.3%
De Silva 1996 “Unacceptable” adverse events
leading to drug withdrawale
PHT (n = 54): drowsiness (n = 2),
skin rash (n = 1) blood dyscrasia (n
= 1), hirsutism (n = 1)
SV (n = 49): behavioural (n = 1),
tremor (n = 1)
Forsythe 1991 No adverse event data reported
(treatmentwithdrawal data only re-
ported)
1 participant (PHT) withdrew
from the study due to depression
and anorexia
No adverse event data (or treatment
withdrawals due to adverse events)
reported
Heller 1995 “Unacceptable” adverse events
leading to drug withdrawale
PHT (n = 63): myalgia (n = 1), ir-
ritability (n = 1)
SV (n = 61): dizziness (n = 2) ab-
normal liver function test (n = 1)
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Table 7. Adverse event data (narrative report) (Continued)
Ramsay 1992 Most common adverse events (by
treatment group)f
PHT (n = 50): dyspepsia (n = 1)
, nausea (n = 2), dizziness (n = 2),
somnolence (n = 5), tremor (n = 2)
, rash (n = 4)
SV (n = 86): dyspepsia (n = 7), nau-
sea (n = 10), dizziness (n = 5), som-
nolence (n = 8), tremor (n = 5), rash
(n = 3)
Rastogi 1991 Commonest adverse events (re-
ported as percentages by treatment
group)f
PHT (n = 45): gum hyperpla-
sia (17.7%), nystagmus (13.33%),
ataxia (2.2%), gastrointestinal dis-
turbances (4.44%), drowsiness (4.
44%)
SV (n = 49): gastrointestinal distur-
bances (12%), drowsiness (6.12%)
, weight gain (2.04%)
Shakir 1981 Adverse events (narrative descrip-
tion)b
PHT (n = 15): 1 case of ataxia, 5
cases of acne
SV (n = 18): 2 cases of gastrointesti-
nal symptoms, 2 cases of hair loss,
4 cases of weight gain
Thilothammal 1996 Assessment of adverse eventsb PHT (n = 52): 33 participants re-
ported at least one side effect
Reported frequencies: gingival hy-
pertrophy (n = 30), ataxia (n = 13),
sedation (n = 12), nausea and vom-
iting (n = 1)
Other reported adverse events (no
frequencies): nystagmus, confusion
SV (n = 48): 15 participants re-
ported at least one side effect
Reported frequencies: hyperactiv-
ity (n = 6), impaired school perfor-
mance (n = 4), severe skin allergy
(n = 1)
Turnbull 1985 Treatment withdrawals due to
dose-related and idiosyncratic ad-
verse events
PHT (n = 70): 11 treatment with-
drawals due to dose-related adverse
events (nystagmus, ataxia, tremor,
diplopia and mental change)
5 treatment withdrawals due to
idiosyncratic adverse events (skin
eruption, erythroderma and jaun-
dice)
SV (n = 70): 9 treatment with-
drawals due to dose-related adverse
events (tremor, irritability, restless-
ness and alopecia)
No treatment withdrawals due to
idiosyncratic adverse events
aAdverse event data, as reported narratively in the publications. Adverse event data were not requested in original IPD requests but will
be for all future IPD requests. For numbers of treatment withdrawals due to adverse events in studies for which IPD were provided
(De Silva 1996; Heller 1995; Ramsay 1992; Turnbull 1985) see Table 5.
bParticipants may report more than one adverse event.
cThe published paper, Craig 1994, reports on a subset of 38 participants, so the adverse event data summary applies only to this subset.
IPD were provided for 166 participants (no additional adverse event data provided).
dCzapinski 1997a is an abstract only so very little information is reported.
eParticipants may have withdrawn due to adverse event alone or a combination of adverse events and poor efficacy (seizures).
fMost commonly reported adverse events only, no indication of overall frequency of all adverse events.
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A P P E N D I C E S
Appendix 1. Cochrane Epilepsy Group’s Specialized Register search strategy
1. MeSH DESCRIPTOR Phenytoin Explode All AND INREGISTER
2. phenytoin or Epanutin or Phenytek or Dilantin or Eptoin or Diphenin or Dipheninum or Diphenylhydantoin AND INREGISTER
3. #1 OR #2 AND INREGISTER
4. MeSH DESCRIPTOR Valproic Acid Explode All AND INREGISTER
5. Depakene or Depacon or Depakine or Valparin or Stavzor or Epilim or Epiject or Episenta or Epival or Valpro* or Orlept or Orfiril
or Selenica or Convulex or Depakote AND INREGISTER
6. #4 OR #5 AND INREGISTER
7. #3 AND #6 AND INREGISTER
8. (adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*):TI AND
INREGISTER
9. #7 NOT #8 AND INREGISTER
10. MeSH DESCRIPTOR Phenytoin Explode All AND CENTRAL:TARGET
11. phenytoin or Epanutin or Phenytek or Dilantin or Eptoin or Diphenin or Dipheninum or Diphenylhydantoin AND CENTRAL:
TARGET
12. #10 OR #11 AND CENTRAL:TARGET
13. MeSH DESCRIPTOR Valproic Acid Explode All AND CENTRAL:TARGET
14. Depakene or Depacon or Depakine or Valparin or Stavzor or Epilim or Epiject or Episenta or Epival or Valpro* or Orlept or Orfiril
or Selenica or Convulex or Depakote AND CENTRAL:TARGET
15. #13 OR #14 AND CENTRAL:TARGET
16. #12 AND #15 AND CENTRAL:TARGET
17. (adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*):TI AND
CENTRAL:TARGET
18. #16 NOT #17 AND CENTRAL:TARGET
19. #9 OR #18
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor: [Phenytoin] explode all trees
#2 Epanutin or Phenytek or Dilantin or Eptoin or Diphenin or Dipheninum or Diphenylhydantoin:ti,ab,kw (Word variations have
been searched)
#3 #1 or #2
#4 MeSH descriptor: [Valproic Acid] explode all trees
#5 Depakene or Depacon or Depakine or Valparin or Stavzor or Epilim or Epiject or Episenta or Epival or Valpro* or Orlept or Orfiril
or Selenica or Convulex or Depakote:ti,ab,kw (Word variations have been searched)
#6 #4 or #5
#7 #3 and #6
#8 (adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*):ti (Word
variations have been searched)
#9 #7 not #8
#10 (epilep* or seizure* or convuls*):ti,ab,kw (Word variations have been searched)
#11 MeSH descriptor: [Epilepsy] explode all trees
#12 MeSH descriptor: [Seizures] explode all trees
#13 (#10 or #11 or #12) in Trials
#14 #9 and #13
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Appendix 3. MEDLINE search strategy
The following search is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE
(Lefebvre 2011).
1. exp phenytoin/ or (Epanutin or Phenytek or Dilantin or Eptoin or Diphenin or Dipheninum or Diphenylhydantoin).mp.
2. exp Valproic Acid/ or (Depakene or Depacon or Depakine or Valparin or Stavzor or Epilim or Epiject or Episenta or Epival or
Valpro$ or Orlept or Orfiril or Selenica or Convulex or Depakote).mp.
3. ((adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$) not (monotherap$ or alone or singl$)).ti.
4. (1 and 2) not 3
5. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. 5 or 6 or 7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Epilepsy/
12. exp Seizures/
13. (epilep$ or seizure$ or convuls$).tw.
14. 11 or 12 or 13
15. exp *Pre-Eclampsia/ or exp *Eclampsia/
16. 14 not 15
17. 4 and 10 and 16
18. remove duplicates from 17
Earlier versions of this review used the following search, based on the previous Cochrane Highly Sensitive Search Strategy forMEDLINE
as set out in Appendix 5b of the Cochrane Handbook for Systematic Reviews of Interventions (version 4.2.4, updated March 2005)
(Higgins 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. exp Randomized Controlled Trials/
4. exp Random Allocation/
5. exp Double-Blind Method/
6. exp Single-Blind Method/
7. clinical trial.pt.
8. Clinical Trial/
9. (clin$ adj trial$).ab,ti.
10. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.
11. exp PLACEBOS/
12. placebo$.ab,ti.
13. random$.ab,ti.
14. exp Research Design/
15. or/1-14
16. (animals not humans).sh.
17. 15 not 16
18. phenytoin/ or (phenytoin or diphenylhydantoin).tw.
19. valproic acid/ or valpro$.tw.
20. exp epilepsy/ or epilep$.tw.
21. exp seizures/ or seizure$.tw.
22. convulsion$.tw.
23. 18 and 19
24. 20 or 21 or 22
25. 23 and 24
26. 17 and 25
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Appendix 4. SCOPUS search strategy
(((TITLE(phenytoin or Epanutin or Phenytek or Dilantin or Eptoin or Diphenin or Dipheninum or Diphenylhydantoin) or
ABS(phenytoin or Epanutin or Phenytek or Dilantin or Eptoin or Diphenin or Dipheninum or Diphenylhydantoin)) and (TI-
TLE(Depakene or Depacon or Depakine or Valparin or Stavzor or Epilim or Epiject or Episenta or Epival or Valpro* or Orlept or
Orfiril or Selenica or Convulex or Depakote) or ABS(Depakene or Depacon or Depakine or Valparin or Stavzor or Epilim or Epiject
or Episenta or Epival or Valpro* or Orlept or Orfiril or Selenica or Convulex or Depakote))) and not (TITLE-ABS-KEY((adjunct* OR
“add-on” OR “add on”) AND NOT monotherap*))) and (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind*
OR unblind* OR “parallel-group” OR “parallel group” OR crossover OR cross-over OR “cross over” OR cluster OR “head to head”
OR “head-to-head”) PRE/2 (trial OR method OR procedure OR study)) OR ABS((randomiz* OR randomis* OR controlled OR
placebo OR blind* OR unblind* OR “parallel-group” OR “parallel group” OR crossover OR cross-over OR “cross over” OR cluster
OR “head to head” OR “head-to-head”) PRE/2 (trial OR method OR procedure OR study))) and ((TITLE-ABS-KEY(epilep* OR
“infantile spasm” OR seizure OR convuls* OR (syndrome W/2 (aicardi OR angelman OR doose OR dravet OR janz OR jeavons
OR “landau kleffner” OR “lennox gastaut” OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR “sturge weber” OR tassi-
nari OR “unverricht lundborg” OR west)) OR “ring chromosome 20” OR “R20” OR “myoclonic encephalopathy” OR “pyridoxine
dependency”) AND NOT (TITLE(*eclampsia) OR INDEXTERMS(*eclampsia))) OR (TITLE-ABS-KEY(lafora* W/4 (disease OR
epilep*)) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine))))
WH A T ’ S N E W
Last assessed as up-to-date: 19 February 2018.
Date Event Description
26 June 2018 New citation required but conclusions have not
changed
Review updated; conclusions are unchanged
19 February 2018 New search has been performed Updated search on 19 February 2018; no new studies
included
The title was changed in line with the titles of other
pairwise monotherapy comparisons in the series (i.e.
’monotherapy for epilepsy’ instead of ’for partial on-
set seizures and generalised onset tonic-clonic seizures’)
and in line with Cochrane guidelines of intervention (i.
e. valproate) first and comparator (i.e. phenytoin) sec-
ond
The term ’partial’ has been replaced by ’focal’, in accor-
dance with the most recent classification of epilepsies
of the International League Against Epilepsy (Scheffer
2017).
Lead author, previously known as Sarah Nolan is now
Sarah Nevitt
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H I S T O R Y
Protocol first published: Issue 3, 1999
Review first published: Issue 4, 2001
Date Event Description
26 April 2017 Amended Declarations of interest section updated
19 May 2015 New search has been performed No new studies included; conclusions unchanged
19 May 2015 New citation required but conclusions have not
changed
Searches updated on 19 May 2015
13 August 2013 New citation required but conclusions have not
changed
Conclusions unchanged
21 February 2013 New search has been performed Searches updated February 2013. Analyses and text
updated. ’Risk of bias’ assessments and ’Summary of
findings’ table added
23 September 2008 Amended Converted to new review format
27 July 2007 New search has been performed We reran our searches on 27 July 2007 and identified
one new study and added it to the ’Characteristics of
studies awaiting classification’ section; we will assess it
for inclusion in the review at a later date
C O N T R I B U T I O N S O F A U T H O R S
SJ Nevitt assessed studies for inclusion in the review update, obtained individual participant data (IPD) from trial investigators for the
review update, assessed risk of bias in all included studies, performed analyses in Stata version 14, added survival plots and a ’Summary
of findings’ table, and updated the text of the review.
AG Marson obtained IPD from trial investigators, provided guidance with the clinical interpretation of results, assessed eligibility and
methodological quality of individual studies and co-wrote the original review.
J Weston independently assessed risk of bias in all included studies.
C Tudur Smith was the lead investigator on the original review, assessed eligibility and methodological quality of original individual
studies, organised and cleaned the IPD sets, performed data validation checks and statistical analyses and co-wrote the original review.
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D E C L A R A T I O N S O F I N T E R E S T
SJ Nevitt has no declarations of interest.
AGMarson: A consortiumof pharmaceutical companies (GSK,EISAI,UCBPharma) funded theNational Audit of SeizureManagement
in Hospitals (NASH) through grants paid to University of Liverpool. Professor Tony Marson is part funded by National Institute for
Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).
J Weston has no declarations of interest.
C Tudur Smith has no declarations of interest.
S O U R C E S O F S U P P O R T
Internal sources
• University of Liverpool, UK.
• Walton Centre for Neurology and Neurosurgery, UK.
External sources
• Medical Research Council, UK.
• National Institute for Health Research (NIHR), UK.
This review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Epilepsy Group.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, National Health Service (NHS) or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the 2018 update: we changed the title in line with the titles of other pair-wise monotherapy comparisons in the series (i.e.
’monotherapy for epilepsy’ instead of ’for focal onset seizures and generalised onset tonic-clonic seizures) and in line with Cochrane
Style guidelines of intervention (i.e. sodium valproate) first and comparator (i.e. phenytoin) second.
We redefined ’time to withdrawal of allocated treatment’ as ’time to treatment failure’ due to feedback received from the Cochrane
Editorial Unit regarding potential confusion regarding ’withdrawal’ as a positive or negative outcome of antiepileptic monotherapy.
We conducted additional analyses of ’time to treatment failure’ (due to lack of efficacy and due to adverse events) following feedback
on published antiepileptic drug monotherapy reviews that these suboutcomes would be useful for clinical practice.
We replaced the term ’partial’ by ’focal’, in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy (Scheffer 2017).
We presented adverse event information as a separate secondary outcome, ’incidence of adverse events’ in line with other Cochrane
IPD reviews investigating pair-wise monotherapy comparisons.
In December 2014, we changed the title to specify that the review uses individual participant data (IPD).
For the 2013 update, in a post hoc change, we added ’Summary of findings’ tables to the review.
We added sensitivity analyses following identification of potential misclassification of seizure type. The existence of misclassification in
the individual studies could not have been known at the time of writing the original protocol.
We added the outcome ’time to six-month remission’ for consistency with the other reviews in the series of Cochrane IPD reviews
investigating pair-wise monotherapy comparisons and removed the outcome ’quality of Life’ which was found to not be readily available
in an analysable format from early IPD requests.
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N O T E S
The protocol for this review was published with Catrin Tudur as the contact review author. Catrin is now known as Catrin Tudur
Smith.
Sarah J Nolan (lead author of the 2013 and 2016 update) is now Sarah J Nevitt.
Jennifer Pulman (author of the 2013 update) is now Jennifer Weston.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [∗therapeutic use]; Epilepsies, Partial [∗drug therapy]; Epilepsy, Generalized [drug therapy]; Epilepsy, Tonic-Clonic
[∗drug therapy]; Phenytoin [∗therapeutic use]; Randomized Controlled Trials as Topic; Seizures [drug therapy]; Valproic Acid
[∗therapeutic use]
MeSH check words
Humans
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